

# PRODUCT MONOGRAPH

<sup>Pr</sup> **XOLAIR**<sup>®</sup>

(omalizumab)

Sterile powder for reconstitution

150 mg vial

IgE-Neutralizing Antibody (Anti-IgE)

Novartis Pharmaceuticals Canada Inc.  
Dorval, Quebec  
H9S 1A9

Date of Approval:  
February 25, 2015

**Control No. 179831**

<sup>Pr</sup> XOLAIR is a registered trademark

## Table of Contents

<b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
INDICATIONS AND CLINICAL USE .....	3
CONTRAINDICATIONS .....	3
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS.....	8
DRUG INTERACTIONS .....	13
DOSAGE AND ADMINISTRATION.....	14
OVERDOSAGE .....	20
ACTION AND CLINICAL PHARMACOLOGY .....	20
STORAGE AND STABILITY.....	22
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	23
<b>PART II: SCIENTIFIC INFORMATION .....</b>	<b>24</b>
PHARMACEUTICAL INFORMATION.....	24
CLINICAL TRIALS.....	25
DETAILED PHARMACOLOGY .....	36
TOXICOLOGY .....	37
REFERENCES .....	46
<b>PART III: CONSUMER INFORMATION.....</b>	<b>52</b>

Pr **XOLAIR**<sup>®</sup>  
(omalizumab)

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Dosage Form / Strength</b>	<b>Clinically Relevant Nonmedicinal Ingredients</b>
subcutaneous	Sterile powder for reconstitution 150 mg vial	sucrose, L-histidine hydrochloride monohydrate, L-histidine and polysorbate 20

**INDICATIONS AND CLINICAL USE**

XOLAIR<sup>®</sup> (omalizumab) is indicated for:

- adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. XOLAIR<sup>®</sup> has been shown to significantly decrease the incidence of asthma exacerbations and improve control of asthma symptoms in these patients.
- the treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria (CIU) who remain symptomatic despite H1 antihistamine treatment.

**The safety and efficacy of XOLAIR<sup>®</sup> have not been established in other conditions.**

**Geriatrics (> 65 years of age):** There is limited experience with XOLAIR<sup>®</sup> in patients over 65 years of age (see **WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics**).

**Pediatrics (< 12 years of age):** XOLAIR<sup>®</sup> is not indicated for children below 12 years of age.

**CONTRAINDICATIONS**

XOLAIR<sup>®</sup> (omalizumab) should not be administered to patients with known hypersensitivity to omalizumab or any component of the formulation (see **SUMMARY PRODUCT INFORMATION**), or patients who have experienced a severe hypersensitivity reaction to XOLAIR<sup>®</sup> (see **WARNINGS AND PRECAUTIONS: Anaphylaxis**).

## WARNINGS AND PRECAUTIONS

### **Serious Warnings and Precautions**

Anaphylaxis, presenting as angioedema of the throat or tongue, bronchospasm, hypotension, syncope, and/or urticaria has been reported to occur after administration of XOLAIR<sup>®</sup>.

Anaphylaxis has occurred as early as after the first dose of XOLAIR<sup>®</sup>, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, patients should be closely observed for an appropriate period of time after XOLAIR<sup>®</sup> administration, and health care providers administering XOLAIR<sup>®</sup> should be prepared to manage anaphylaxis that can be life-threatening. Patients should also be informed of the signs and symptoms of anaphylaxis and instructed to seek immediate medical care should symptoms occur (see WARNINGS AND PRECAUTIONS, Information for Patients).

### **General**

XOLAIR<sup>®</sup> (omalizumab) has not been shown to alleviate asthma exacerbations acutely and should not be used for the treatment of acute bronchospasm or status asthmaticus.

### **Anaphylaxis**

Anaphylaxis has been reported to occur after administration of XOLAIR<sup>®</sup> in premarketing clinical trials and in postmarketing spontaneous reports (See ADVERSE REACTIONS). Signs and symptoms in these reported cases have included angioedema of the throat or tongue, bronchospasm, hypotension, syncope, and/or urticaria. Some of these events have been life-threatening. In premarketing clinical trials the frequency of anaphylaxis attributed to XOLAIR<sup>®</sup> use was estimated to be 0.1%. In post marketing spontaneous reports, the frequency of anaphylaxis attributed to XOLAIR<sup>®</sup> use was estimated to be at least 0.2% of patients based on an estimated exposure of about 57,300 patients from June 2003 through December 2006. Anaphylaxis and anaphylactoid reactions have been reported following the first or subsequent administrations of XOLAIR<sup>®</sup>. Although most of these reactions occurred within 2 hours, some occurred beyond 2 hours. Anaphylaxis has occurred as early as after the first dose of XOLAIR<sup>®</sup>, but also has occurred beyond one year after beginning regularly scheduled treatment.

XOLAIR<sup>®</sup> should only be administered in a healthcare setting by healthcare providers prepared to manage anaphylaxis that can be life-threatening. Patients should be closely observed for an appropriate period of time after administration of XOLAIR<sup>®</sup>, taking into account the time to onset of anaphylaxis seen in premarketing clinical trials and postmarketing spontaneous reports (see ADVERSE REACTIONS). Patients should be informed of the signs and symptoms of anaphylaxis, and instructed to seek immediate medical care should signs or symptoms occur (see Information for Patients).

XOLAIR<sup>®</sup> should be discontinued in patients who experience a severe hypersensitivity reaction (see CONTRAINDICATIONS).

## **Cardiovascular and Cerebrovascular disorders**

In controlled clinical trials in adults and adolescents 12 years of age and older, cerebrovascular events including transient ischaemic attack and ischaemic stroke were observed in patients treated with XOLAIR<sup>®</sup>. (See Adverse Reactions).

In a 5 year observational study, a disproportionate increase of overall cardiovascular and cerebrovascular disorders was observed in the XOLAIR<sup>®</sup> cohort compared to the non-XOLAIR<sup>®</sup> cohort (see Adverse Reactions).

## **Corticosteroid Reduction**

Systemic or inhaled corticosteroids should not be abruptly discontinued upon initiation of XOLAIR<sup>®</sup> therapy. Decreases in corticosteroids should be performed under the direct supervision of a physician and may need to be performed gradually.

## **Immune System disorders**

### ***Churg-Strauss syndrome and hypereosinophilic syndrome {wording as per SPC}***

Patients with severe asthma may rarely present systemic hypereosinophilic syndrome or allergic eosinophilic granulomatous vasculitis (Churg-Strauss syndrome), both of which are usually treated with systemic corticosteroids. In rare cases, patients on therapy with anti-asthma agents, including omalizumab, may present or develop systemic eosinophilia and vasculitis. These events are commonly associated with the reduction of oral corticosteroid therapy. In these patients, physicians should be alert to the development of marked eosinophilia, vasculitic rash, worsening pulmonary symptoms, paranasal sinus abnormalities, cardiac complications, and/or neuropathy.

### ***Serum sickness***

Serum sickness and serum sickness-like reactions, which are delayed allergic type III reactions, have rarely been seen in patients treated with humanized monoclonal antibodies including omalizumab. The onset has typically been 1-5 days after administration of the first or subsequent injections, also after long duration of treatment. Symptoms suggestive of serum sickness include arthritis/arthralgia, rash (urticaria or other forms), fever and lymphadenopathy. Antihistamines and corticosteroids may be useful for preventing or treating this disorder, and patients should be advised to report any suspected symptoms.

### ***Immunogenicity***

As with all DNA derived humanized monoclonal antibodies patients may rarely (1 out of 1723 patients, <0.1%) develop antibodies to omalizumab (See ADVERSE REACTIONS).

Discontinuation of omalizumab should be considered in all severe cases of Churg-Strauss syndrome, hypercosinophilic syndrome and serum sickness.

## **Information for Patients**

Patients should be advised of the risk of life-threatening anaphylaxis with XOLAIR<sup>®</sup> and that there have been reports of anaphylaxis up to 4 days after administration of XOLAIR<sup>®</sup>. XOLAIR<sup>®</sup> should only be administered in a healthcare setting by healthcare providers. Patients should be closely observed following its administration. Patients should be informed of the signs and symptoms of anaphylaxis. Patients should be instructed to seek immediate medical care should such signs or symptoms occur. (see WARNINGS AND PRECAUTIONS, Anaphylaxis).

Asthma patients receiving XOLAIR<sup>®</sup> should be instructed not to decrease the dose of or stop taking any other asthma medications unless otherwise instructed by their physician. Asthma patients should be told that they may not see immediate improvement in their asthma after beginning XOLAIR<sup>®</sup> therapy.

Patients receiving XOLAIR<sup>®</sup> should be informed that if they experience dizziness, fatigue, syncope or somnolence, they should not drive or use machines.

### **Other IgE-Associated disorders**

XOLAIR<sup>®</sup> has not been studied in patients with hyperimmunoglobulin E syndrome, allergic bronchopulmonary aspergillosis, or for the prevention of anaphylactic reactions. XOLAIR<sup>®</sup> has not been adequately studied in food allergy, atopic dermatitis, allergic rhinitis, or parasitic infestations.

### **Parasitic (helminth) infections**

IgE may be involved in the immunological response to some helminth infections. In patients at chronic high risk of helminth infection, a placebo-controlled trial in asthma/perennial allergic rhinitis patients showed a slight increase in infection rate with omalizumab, although the course, severity, and response to treatment of infection were unaltered. The helminth infection rate in the overall clinical program, which was not designed to detect such infections, was less than 1 in 1,000 patients. However, caution may be warranted in patients at high risk of helminth infection, in particular when travelling to areas where helminthic infections are endemic. If patients do not respond to recommended anti-helminth treatment, discontinuation of XOLAIR<sup>®</sup> should be considered.

### **Renal or Hepatic impairment**

XOLAIR<sup>®</sup> therapy has not been studied in patients with pre-existing renal or hepatic impairment. Caution should be exercised when administering XOLAIR<sup>®</sup> in these patient populations.

### **Special Populations**

#### **Pregnant Women:**

IgG molecules are known to cross the placental barrier. The safety and efficacy of XOLAIR<sup>®</sup> in pregnant women has not been established. Because animal reproduction studies are not always predictive of human response, XOLAIR<sup>®</sup> should be used during pregnancy only if clearly needed.

Reproduction studies in cynomolgus monkeys have been conducted with omalizumab. Subcutaneous doses up to 75 mg/kg per week (10-fold the highest recommended clinical dose in mg/kg over a 4-week period) of omalizumab did not elicit maternal toxicity, embryotoxicity, or

teratogenicity when administered throughout organogenesis and did not elicit adverse effects on fetal or neonatal growth when administered throughout late gestation, delivery, and nursing.

**Nursing Women:**

While XOLAIR<sup>®</sup> presence in human milk has not been studied, IgG is excreted in human milk and therefore it is expected that XOLAIR<sup>®</sup> will be present in human milk. The potential for XOLAIR<sup>®</sup> absorption or harm to the infant are unknown; caution should be exercised when administering XOLAIR<sup>®</sup> to a nursing woman.

The excretion of omalizumab in milk was evaluated in female cynomolgus monkeys receiving SC doses of 75 mg/kg/week. Neonatal serum levels of omalizumab after *in utero* exposure and 28 days of nursing were between 11% and 94% of the maternal serum level. Milk levels of omalizumab were 0.15% of the maternal serum concentration.

Although no clinically significant effects on platelets have been observed in patients, doses of omalizumab in excess of the clinical dose have been associated with age-dependent decreases in blood platelets in non-human primates, with a greater relative sensitivity in juvenile animals. In reproduction studies in cynomolgus monkeys, there was no clinical evidence of thrombocytopenia in neonatal monkeys from mothers treated up to 75 mg/kg omalizumab; however, platelet counts were not measured in these offspring.

**Fertility:**

There are no human fertility data for omalizumab. In specifically-designed non clinical fertility studies in adult cynomolgus monkeys, including mating studies, no impairment of male or female fertility was observed following repeated dosing with omalizumab at dose levels up to 75 mg/kg.

**Pediatrics (<12 years of age):**

The safety and efficacy of XOLAIR<sup>®</sup> in children below the age of 12 have not been established and use of XOLAIR<sup>®</sup> in such patients is therefore not recommended.

**Geriatrics (> 65 years of age):**

In Phase III clinical trials, 145 asthma patients and 37 CIU patients, 65 years of age or older were treated with XOLAIR<sup>®</sup>. Although there were no apparent age-related differences observed in these studies, the number of patients aged 65 and over is not sufficient to determine whether they respond differently from younger patients.

**Monitoring and Laboratory Tests**

There has been no evidence of clinically significant abnormalities in laboratory tests following treatment with XOLAIR<sup>®</sup>.

Serum total IgE levels increase following administration of XOLAIR<sup>®</sup> due to formation of omalizumab:IgE complexes (See ACTION AND CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION). Elevated serum total IgE levels may persist for up to 1 year following discontinuation of XOLAIR<sup>®</sup>. Serum total IgE levels obtained less than 1 year following discontinuation may not reflect steady state free IgE levels and should not be used to

reassess the dosing regimen in asthma patients.

## **ADVERSE REACTIONS**

### **Asthma**

#### **Adverse Drug Reaction Overview**

The adverse reactions most commonly observed among patients treated with XOLAIR<sup>®</sup> (omalizumab) in pre-marketing clinical studies included injection site reaction (45%), viral infections (24%), upper respiratory tract infection (19%), sinusitis (16%), headache (15%), and pharyngitis (10%). These events were observed at similar rates in XOLAIR<sup>®</sup>-treated patients and control patients.

The occurrence of adverse events resulting in clinical intervention (e.g. discontinuation of XOLAIR<sup>®</sup>, or the need for concomitant medication to treat an adverse reaction) was extremely small; 0.1 % or less.

The data described above reflect XOLAIR<sup>®</sup> exposure for 2285 adult and adolescent patients ages 12 and older, including 1891 patients exposed for six months and 555 exposed for one year or more, in either placebo-controlled or other controlled asthma studies. The mean age of patients receiving XOLAIR<sup>®</sup> was 41 years, 59% were women, and 86% Caucasian. Patients received XOLAIR<sup>®</sup> 150 to 375 mg every 2 or 4 weeks or, for patients assigned to control groups, standard therapy with or without a placebo.

The frequency of adverse events was comparable between the XOLAIR<sup>®</sup> and placebo groups (85.1% vs. 84.0%, respectively). The majority of these adverse events were regarded as mild or moderate in intensity. Treatment discontinuation due to an adverse event occurred more frequently in the placebo group compared with the XOLAIR<sup>®</sup>-treated group (1.4% vs. 0.5%, respectively).

The table below shows adverse events that occurred  $\geq 1\%$  more frequently in patients receiving XOLAIR<sup>®</sup> than in those receiving placebo in the placebo controlled asthma studies. Adverse events were classified using preferred terms from the International Medical Nomenclature (IMN) dictionary. Injection site reactions were recorded separately from the reporting of other adverse events and are described following the table.

## Clinical Trial Adverse Drug Reactions

**Table 1 - All Adverse Events Occurring  $\geq$  1% More Frequently in XOLAIR<sup>®</sup>-Treated Asthma Patients 12 to 75 years of Age Compared with Placebo, Regardless of Causality Assessment.**

Adverse Event	XOLAIR <sup>®</sup> (n=947) Number (%) of Patients Reporting the Event	Placebo (n=913) Number (%) of Patients Reporting the Event
<b>Any Adverse Event</b>	806 (85.1)	767 (84.0)
<b>Body as a whole</b>		
Pain	51 (5.4)	40 (4.4)
<b>Musculoskeletal system</b>		
Fracture	20 (2.1)	10 (1.1)
Leg pain	26 (2.7)	14 (1.5)
<b>Nervous system</b>		
Dizziness	24 (2.5)	15 (1.5)

### Less Common Clinical Trial Adverse Drug Reactions (<1%)

#### *Allergic Events*

As with any protein, local or systemic allergic reactions can occur (See WARNINGS AND PRECAUTIONS). Anti-therapeutic antibody development and allergic symptoms, including urticaria, dermatitis, and pruritus were observed in patients treated with XOLAIR<sup>®</sup>. There were 3 cases out of 3854 (< 0.1%) of anaphylaxis observed within 2 hours of XOLAIR<sup>®</sup> administration in which there were no other identifiable allergic triggers. Anaphylaxis occurred with the first dose of XOLAIR<sup>®</sup> in two patients, and with the fourth dose in one patient. The time to onset of anaphylaxis was 90 minutes after administration in two patients and 2 hours after administration in one patient. These events included urticaria and throat and/or tongue edema. In the clinical studies the frequencies of all allergic-type events including anaphylaxis were similar in XOLAIR<sup>®</sup>-treated patients and control patients.

#### *Cardiovascular and Cerebrovascular events*

During interim analysis of an observational study, an imbalance of cardiovascular and cerebrovascular serious adverse events was observed in the XOLAIR<sup>®</sup> group compared to the non-XOLAIR<sup>®</sup> group. The final analysis of the results of the observational study showed the rate of cardiovascular and cerebrovascular events per 1000 patient years was 17.34 (265/15286 patient years) for XOLAIR<sup>®</sup>-treated patients and 11.44 (114/9963) for control patients. The Cox proportional hazards models adjusting for confounders and risk factors resulted in a hazard ratio of 1.62 (95% [1.23-2.13]). Cardiovascular and cerebrovascular events in which increases in rates were observed include myocardial infarction, unstable angina, transient ischemic attack, pulmonary embolism, and venous thrombosis.

The rate of arterial thromboembolic events (ATEs) in the observational study per 1000 patient years was 7.52 (115/15286 patients years) for XOLAIR<sup>®</sup>-treated patients and 5.12 (51/9963 patient years) for control patients. The Cox proportional hazards models adjusting for

confounders and risk factors resulted in a hazard ratio of 1.32 (95%, [0.91, 1.91]). In a further analysis of randomized, double-blind, placebo-controlled clinical trials of 8 or more weeks duration including 3342 patients on XOLAIR<sup>®</sup> and 2895 patients on placebo, the rate of ATE per 1000 patient years was 2.69 (5/1856 patients years) for XOLAIR<sup>®</sup>-treated patients and 2.38 (4/1680 patient years) for placebo patients (rate ratio 1.13, 95%, [0.24-5.71]). The observed incidence rate of arterial thromboembolic events in the XOLAIR<sup>®</sup> controlled clinical trials was comparable to that reported in the general asthma population.

### *Malignancies*

During initial clinical trials for adults and adolescents 12 years of age and older, there was a numerical imbalance in malignancies arising in the active treatment group, compared with the control group. The number of observed cases was uncommon (<1/100) in both the active and the control group. Malignant neoplasms were observed in 25 of 5015 (0.5%) XOLAIR<sup>®</sup>-treated patients compared with 5 of 2854 (0.2%) control patients in clinical studies of asthma and other allergic disorders. The observed malignancies in XOLAIR<sup>®</sup>-treated patients were a variety of types, with breast, non-melanoma skin, prostate, melanoma, and parotid occurring more than once, and five other types occurring once each. The diversity in the type of cancers observed, the relatively short duration of exposure and the clinical features of the individual cases render a causal relationship unlikely. In a subsequent observational study comparing 5007 XOLAIR<sup>®</sup>-treated and 2829 non-XOLAIR<sup>®</sup>-treated patients followed for up to 5 years, the incidence rates of primary malignancies per 1000 patient years were 16.01 (295/18426 patient years) and 19.07 (190/9963 patients years), respectively, which does not indicate an increased malignancy risk (rate ratio 0.84, 95% confidence interval, 0.62-1.13). In a further analysis of randomized, double-blind, placebo-controlled clinical trials including 4254 patients on XOLAIR<sup>®</sup> and 3178 patients on placebo, XOLAIR<sup>®</sup> treatment was not associated with an increased malignancy risk based on incidence rates per 1000 patient years of 4.14 (14/3382 patient years) for XOLAIR<sup>®</sup> treated patients and 4.45 (11/2474 patient years) for placebo patients (rate ratio 0.93, 95%, [0.39-2.27]). The overall observed incidence rate of malignancy in the XOLAIR<sup>®</sup> clinical trial program was comparable to that reported in the general population.

### *Injection Site Reactions*

Injection site reactions of any severity occurred at a rate of 45% in XOLAIR<sup>®</sup>-treated patients compared with 43% in placebo-treated patients. The types of injection site reactions included: bruising, redness, warmth, burning, stinging, itching, hive formation, pain, indurations, mass, and inflammation. Most were regarded as mild or moderate in intensity and did not require discontinuation of therapy. Severe injection site reactions occurred more frequently in XOLAIR<sup>®</sup> treated patients compared with patients in the placebo group (12% versus 9%).

The majority of injection site reactions occurred within 1 hour post injection, lasted less than 8 days, and generally decreased in frequency at subsequent dosing visits.

### *Asthma Exacerbations Leading to Hospitalizations*

In the pivotal asthma studies, a statistically significant (six-fold) reduction in the number of hospitalizations due to serious asthma exacerbation was observed in the XOLAIR<sup>®</sup> treated group compared to placebo group (13 vs 2, respectively, p=0.004).

### Long-Term Adverse Effects (Up to 1 Year)

With long-term treatment, the adverse event profile did not significantly change and patients continued to tolerate XOLAIR® well.

## **Chronic Idiopathic Urticaria (CIU)**

### **Adverse Drug Reaction Overview**

The safety and tolerability of omalizumab were investigated with the doses of 75 mg, 150 mg and 300 mg every four weeks in 975 CIU patients, 242 of whom received placebo. 733 patients were treated with omalizumab for up to 12 weeks and 490 patients for up to 24 weeks. 175 and 412 patients were treated for up to 12 weeks and 87 and 333 patients were treated for up to 24 weeks at the recommended doses of 150 mg and 300 mg respectively.

During clinical studies with adult and adolescent patients (12 years of age and older) the most commonly reported adverse reactions observed were headache and nasopharyngitis.

### **Clinical Trial Adverse Drug Reactions**

Adverse reactions (events occurring in  $\geq 1\%$  of patients in any treatment group and  $\geq 2\%$  more frequently in any omalizumab treatment group than in the placebo group after medical review) reported at the 150 mg and 300mg doses in the three pooled Phase III studies are listed by MedDRA system organ class (Table 2). Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions listed first.

**Table 2 - All Adverse Events Occurring  $\geq 1\%$  More Frequently in XOLAIR®-Treated CIU Patients 12 to 75 years of Age Compared with Placebo, Regardless of Causality Assessment between Day 1 and Week 12 in either XOLAIR® 150 mg or 300 mg**

Adverse Reactions (By Meddra Preferred Term)	Omalizumab Asteria I, Asteria II and Glacial Studies Pooled		
	Omalizumab 150 mg (N=175)	Omalizumab 300 mg (N=412)	Placebo (N=242)
<b>Ear and labyrinth disorders</b>			
Vertigo	2 (1.14%)	1 (0.24%)	2(0.83%)
<b>Gastrointestinal disorders</b>			
Diarrhea	2 (1.14%)	12 (2.91%)	7 (2.89%)
Nausea	2 (1.14%)	11 (2.67%)	6 (2.48%)
Abdominal Pain Upper	2 (1.14%)	2 (0.49%)	2 (0.83%)
Flatulence	2 (1.14%)	2 (0.49%)	0 (0.00%)
Toothache	2 (1.14%)	2 (0.49%)	1 (0.41%)
Abdominal Pain	3 (1.71%)	1 (0.24%)	4 (1.65%)
<b>General disorders and administration site conditions</b>			
Fatigue	0 (0.00%)	7 (1.70%)	3 (1.24%)
Oedema Peripheral	3 (1.71%)	4 (0.97%)	1 (0.41%)
Influenza Like Illness	2 (1.14%)	1 (0.24%)	0 (0.00%)
<b>Infections and infestations</b>			
Nasopharyngitis	16 (9.14%)	27 (6.55%)	17 (7.02%)
Sinusitis	2 (1.14%)	20 (4.85%)	5 (2.07%)

Upper Respiratory Tract Infection	2 (1.14%)	14 (3.40%)	5 (2.07%)
Urinary Tract Infection	3 (1.71%)	6 (1.46%)	1 (0.41%)
Viral Upper Respiratory Tract Infection	4 (2.29%)	2 (0.49%)	0 (0.00%)
Fungal Infection	3 (1.71%)	2 (0.49%)	1 (0.41%)
Pharyngitis	2 (1.14%)	1 (0.24%)	0 (0.00%)
<b>Musculoskeletal and connective tissue disorders</b>			
Arthralgia	5 (2.86%)	12 (2.91%)	1 (0.41%)
Pain In Extremity	3 (1.71%)	4 (0.97%)	1 (0.41%)
Musculoskeletal Pain	3 (1.71%)	0 (0.00%)	1 (0.41%)
Bursitis	2 (1.14%)	0 (0.00%)	0 (0.00%)
<b>Nervous system disorders</b>			
Headache	21 (12.00%)	25 (6.07%)	7 (2.89%)
Presyncope	2 (1.14%)	3 (0.73%)	0 (0.00%)
<b>Respiratory, thoracic and mediastinal disorders</b>			
Cough	2 (1.14%)	9 (2.18%)	3 (1.24%)
Asthma	1 (0.57%)	5 (1.21%)	1 (0.41%)
Nasal Congestion	2 (1.14%)	3 (0.73%)	2 (0.83%)
Oropharyngeal Pain	3 (1.71%)	2 (0.49%)	4 (1.65%)
<b>Skin and subcutaneous tissue disorders</b>			
Alopecia	1 (0.57%)	6 (1.46%)	2 (0.83%)
Eczema	2 (1.14%)	4 (0.97%)	2 (0.83%)
Dry Skin	2 (1.14%)	0 (0.00%)	0 (0.00%)
<b>Vascular disorders</b>			
Hypertension	2 (1.14%)	2 (0.49%)	1 (0.41%)

Additional events reported anytime during the day 1 to week 24 treatment period (ASTERIA I and GLACIAL studies) that met the criteria of adverse reactions:

Musculoskeletal and connective tissue disorders: myalgia (placebo 0%, 150 mg 2.3%, 300 mg 0.9%).

General disorders and administration site conditions: pyrexia (placebo 1.2%, 150 mg 3.4%, 300 mg 0.9%).

Injection site reactions: Injection site reactions occurred during the studies in more omalizumab-treated patients than placebo patients (2.7% at 300 mg, 0.6% at 150 mg, 0.8% with placebo). These included: swelling, erythema, pain, bruising, itching, bleeding and urticaria.

### **Postmarketing Adverse Drug Reactions**

The following reactions have been identified through spontaneous reportings in asthma patients.

*Immune system disorders:* Anaphylaxis and anaphylactoid reactions have uncommonly been reported following the first or subsequent administrations; serum sickness has been rarely reported.

Anaphylaxis: Based on spontaneous reports and an estimated exposure of about 57,300 patients from June 2003 through December 2006, the frequency of anaphylaxis attributed to XOLAIR<sup>®</sup> use was estimated to be at least 0.2% of patients. Diagnostic criteria of anaphylaxis were skin or mucosal tissue involvement, and, either airway compromise, and/or reduced blood pressure with or without associated symptoms, and a temporal relationship to XOLAIR<sup>®</sup> administration with no other identifiable cause. Signs and symptoms in these reported cases included angioedema of the throat or tongue, bronchospasm, chest tightness, cough, cutaneous angioedema, dyspnea, hypotension, syncope, and/or urticaria. Pulmonary involvement was reported in 89% of the cases. Hypotension or syncope was reported in 14% of cases. A previous history of anaphylaxis unrelated to XOLAIR<sup>®</sup> was reported in 24% of the cases.

Of the reported cases of anaphylaxis attributed to XOLAIR<sup>®</sup>, 39% occurred with the first dose, 19% occurred with the second dose, 10% occurred after the third dose, and the rest after subsequent doses. One case occurred after 39 doses (after 19 months of continuous therapy followed by a 3 month gap, anaphylaxis occurred upon restarting). The time to onset of anaphylaxis in these cases was 30 minutes or less in 35%, 30 to less than 60 minutes in 16%, 60 to less than 90 minutes in 2%, 90 to less than 120 minutes in 6%, 2 hours to 6 hours in 5%, 6 to 12 hours in 14%, 12 to 24 hours in 8%, 24 hours to 48 hours in 2% and 48 hours to 4 days in 2%. In 9% of cases the times to onset were unknown.

Fifteen percent of the reported cases resulted in hospitalization. Twenty-three patients who experienced anaphylaxis were re-challenged with XOLAIR<sup>®</sup> and 18 had a recurrence of similar symptoms of anaphylaxis. Four patients who received XOLAIR<sup>®</sup>, from all reported anaphylaxis cases, experienced urticaria and upon re-exposure developed anaphylaxis.

*Blood and lymphatic system disorders:* idiopathic severe thrombocytopenia

*Musculoskeletal and connective tissue disorders:* arthralgia, myalgia, joint swelling.

*Respiratory, thoracic and mediastinal disorders:* allergic granulomatous angiitis (i.e. Churg Strauss syndrome).

*Skin and subcutaneous disorders:* alopecia.

## **DRUG INTERACTIONS**

### **Overview**

No formal drug interaction studies have been performed with XOLAIR<sup>®</sup> (omalizumab).

### **Drug-Drug Interactions**

Cytochrome P<sub>450</sub> enzymes, efflux pumps and protein binding mechanisms are not involved in the clearance of omalizumab; thus, there is little potential for drug-drug interactions. There is no pharmacological reason to expect that commonly prescribed medications used in the treatment of asthma or CIU will interact with omalizumab.

**Asthma**

In clinical studies XOLAIR<sup>®</sup> was commonly used in conjunction with inhaled and oral corticosteroids, inhaled short-acting and long-acting beta agonists, leukotriene modifiers, theophyllines and oral antihistamines. There was no indication that safety of XOLAIR<sup>®</sup> was altered with these other commonly used asthma medications. The concomitant use of XOLAIR<sup>®</sup> and allergen immunotherapy has not been evaluated.

**Chronic Idiopathic Urticaria**

In CIU clinical studies, XOLAIR<sup>®</sup> was used in conjunction with antihistamines (anti-H1, anti-H2) and leukotriene receptor antagonists (LTRAs). There was no evidence that the safety of omalizumab was altered when used with these medicinal products relative to its known safety profile in asthma. In addition, a population pharmacokinetic analysis showed no relevant effect of H2 antihistamines and LTRAs on omalizumab pharmacokinetics (see ACTION AND CLINICAL PHARMACOLOGY).

The combination of XOLAIR<sup>®</sup> with immunosuppressive therapies has not been studied in patients with CIU.

**DOSAGE AND ADMINISTRATION****Dosing Considerations for Asthma**

XOLAIR<sup>®</sup> (omalizumab) 150 to 375 mg is administered SC every 2 or 4 weeks. See the dose determination charts below for appropriate dose assignment. Doses (mg) and dosing frequency are determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site. Because the solution is slightly viscous, the injection may take 5-10 seconds to administer.

The need for continued therapy should be periodically reassessed based upon the patient's disease severity and level of asthma control.

**Recommended Dose and Dosage Adjustment for Asthma Patients**

**ADMINISTRATION EVERY 4 WEEKS.**

**XOLAIR® doses (milligrams per dose) administered by subcutaneous injection every 4 weeks**

Baseline IgE*	Body weight (kg)									
	≥20–30	>30–40	>40–50	>50–60	>60–70	>70–80	>80–90	>90–125	>125–150	
≥30–100 IU/mL or ≥72–240 ng/mL	150	150	150	150	150	150	150	300	300	
>100–200 IU/mL or >240–480 ng/mL	150	150	300	300	300	300	300	<b>SEE ADMINISTRATION EVERY 2 WEEKS TABLE</b>		
>200–300 IU/mL or >480–720 ng/mL	150	300	300	300						
>300–400 IU/mL or >720–960 ng/mL	300	300								
>400–500 IU/mL or >960–1200 ng/mL	300									
>500–600 IU/mL or >1200–1440 ng/mL	300									
>600–700 IU/mL or >1440–1680 ng/mL										

**\*1 IU /mL = 2.4 ng/mL = 2.4 mcg / L**

**ADMINISTRATION EVERY 2 WEEKS**  
**XOLAIR® doses (milligrams per dose) administered by subcutaneous injection every 2 weeks**

	Body weight (kg)								
Baseline IgE*	≥20–30	>30–40	>40–50	>50–60	>60–70	>70–80	>80–90	>90-125	>125–150
≥30-100 IU/mL or ≥72-240 ng/mL	<b>SEE ADMINISTRATION EVERY 4 WEEKS TABLE</b>								
>100–200 IU/mL or >240-480 ng/mL									
>200–300 IU/mL or >480-720 ng/mL				225	225	225	300	375	
>300–400 IU/mL or >720-960 ng/mL			225	225	225	300	300	<b>DO NOT DOSE</b>	
>400–500 IU/mL or >960-1200 ng/mL		225	225	300	300	375	375		
>500–600 IU/mL or >1200-1440 ng/mL		225	300	300	375				
>600–700 IU/mL or >1440-1680 ng/mL	225	225	300	375					

\*1 IU /mL = 2.4 ng/mL = 2.4 mcg / L

### *Dosing Adjustments*

Total IgE levels are elevated during treatment and remain elevated for up to one year after the discontinuation of treatment. Therefore, re testing of IgE levels during XOLAIR<sup>®</sup> treatment cannot be used as a guide for dose determination. Dose determination after treatment interruptions lasting less than 1 year should be based on serum IgE levels obtained at the initial dose determination. Total serum IgE levels may be re tested for dose determination if treatment with XOLAIR<sup>®</sup> has been interrupted for one year or more.

Doses should be adjusted for significant changes in body weight (See dosing charts under Recommended Dose and Dosage Adjustment).

### **Dosing Considerations for Chronic Idiopathic Urticaria**

XOLAIR<sup>®</sup> (omalizumab) 150 mg or 300 mg are administered subcutaneously every 4 weeks. The efficacy of XOLAIR<sup>®</sup> in CIU patients is dose dependent (see PART II, CLINICAL TRIALS, Chronic Idiopathic Urticaria).

Prescribers are advised to periodically reassess the need for continued therapy. Clinical trial experience of long-term treatment beyond 6 months in this indication is limited.

Dosing of XOLAIR<sup>®</sup> in CIU patients is not dependent on serum IgE (free or total) level or body weight.

### **Renal or hepatic impairment**

There have been no studies on the effect of impaired renal or hepatic function on the pharmacokinetics of XOLAIR<sup>®</sup>. While no particular dose adjustment is recommended, XOLAIR<sup>®</sup> should be administered with caution in these patients (see WARNINGS AND PRECAUTIONS).

### **Missed Dose**

Patients who miss a dose of XOLAIR<sup>®</sup> should be advised to contact their doctor to find out when to take their next dose of XOLAIR<sup>®</sup>.

### **Administration**

#### **Reconstitution:**

#### **Parenteral Products:**

Vial Size	Volume of Diluent to be Added to Vial	Approximate Available Volume	Nominal Concentration per mL
5 cc	1.4 mL	1.2 mL	150 mg per 1.2 mL (125 mg/mL)

Please read carefully before reconstitution. Failure to do so may result in unusable product.

XOLAIR<sup>®</sup> for subcutaneous administration should be prepared using sterile water for injection (SWFI), USP ONLY.


XOLAIR<sup>®</sup> is for single use only. It is recommended that XOLAIR<sup>®</sup> be used immediately following reconstitution (i.e. within 4 hours) as there is no preservative in the formulation. Physicochemical stability studies have shown that the reconstituted product may be stored at 2° - 8°C for up to 8 hours and for 4 hours at 30°C, if the recommended reconstitution procedures are followed.

The lyophilized product takes 15-20 minutes to dissolve. The fully reconstituted product will appear clear or slightly opalescent and may have a few small bubbles or foam around the edge of the vial. The reconstituted product is somewhat viscous; in order to obtain the full 1.2 mL dose ALL OF THE PRODUCT MUST BE WITHDRAWN from the vial before expelling any air or excess solution from the syringe.

**STEP 1:** Draw 1.4 mL of SWFI, USP into a 3-cc syringe equipped with a 1 inch, 18 gauge needle.



**STEP 2:** Place the vial upright on a flat surface and using standard aseptic technique, insert the needle and inject the SWFI, USP directly onto the product.



**STEP 3:** Keeping the vial upright, gently swirl the upright vial for approximately 1 minute to evenly wet the powder. Do not shake.




**STEP 4:** After completing STEP 3, gently swirl the vial for 5 to 10 seconds approximately every 5 minutes in order to dissolve any remaining solids. There should be no visible gel-like particles in the solution. Do not use if foreign particles are present.

Note: Some vials may take longer than 20 minutes to dissolve completely. If this is the case, repeat STEP 4 until there are no visible gel like particles in the solution. It is acceptable to have small bubbles or foam around the edge of the vial. Do not use if the contents of the vial do not dissolve completely by 40 minutes.

STEP 5: Invert the vial for 15 seconds in order to allow the solution to drain toward the stopper. Using a new 3-cc syringe equipped with a 1 inch, 18 gauge needle, insert the needle into the inverted vial. Position the needle tip at the very bottom of the solution in the vial stopper when drawing the solution into the syringe. Before removing the needle from the vial, pull the plunger all the way back to the end of the syringe barrel in order to remove all of the solution from the inverted vial.



STEP 6: Replace the 18 gauge needle with a 25 gauge needle for subcutaneous injection.



STEP 7: Expel air, large bubbles, and any excess solution in order to obtain the required 1.2 mL dose. A thin layer of small bubbles may remain at the top of the solution in the syringe. Because the solution is slightly viscous, the injection may take 5 to 10 seconds to administer.

A vial delivers 1.2 mL (150 mg) of XOLAIR®. For a 75 mg dose, draw up 0.6 mL into the syringe and discard the remaining product (see Table below).

As with all parenteral admixtures, the constituted product should be examined for the presence of foreign particles, agglomeration or discoloration. Any defective units should be discarded.

Number of Injections and Total Injection Volumes for Asthma Patients

Dose (mg)	Number of Injections (vials needed)	Total Volume Injected (mL) <sup>a</sup>
150	1	1.2
225	2	1.8
300	2	2.4
375	3	3

<sup>a</sup> 1.2 mL maximum delivered volume per 150 mg vial.

Number of Injections and Total Injection Volumes for CIU Patients

Dose (mg)	Number of Injections (vials needed)	Total Volume Injected (mL) <sup>a</sup>
150	1	1.2
300	2	2.4

<sup>a</sup> 1.2 mL maximum delivered volume per 150 mg vial.

## OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

The maximum tolerated dose of XOLAIR<sup>®</sup> has not been determined. Single intravenous doses up to 4000 mg have been administered to patients without evidence of dose-limiting toxicities. The highest cumulative dose administered to patients was 44,000 mg over a 20-week period, which was not associated with toxicities.

## ACTION AND CLINICAL PHARMACOLOGY

XOLAIR<sup>®</sup> (omalizumab), an IgE blocker, is a breakthrough recombinant DNA-derived humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). The antibody is an IgG1 kappa that contains human framework regions with the complementarity-determining regions of a murine antibody that binds to IgE.

XOLAIR<sup>®</sup> is produced by a Chinese Hamster Ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin. Gentamicin is not detectable in the final product.

### Mechanism of Action

Omalizumab binds to IgE and prevents binding of IgE to the high-affinity IgE Receptor, FcεRI, thereby reducing the amount of free IgE that is available to trigger the allergic-inflammatory cascade.

### **Asthma**

Treatment of atopic subjects with omalizumab resulted in a significant ( $p=0.0022$ ) marked down-regulation of FcεRI receptors on basophils. Furthermore, the in-vitro histamine release from basophils isolated from omalizumab treated subjects was reduced by approximately 90% following stimulation with an allergen compared to pre-treatment values.

### **Chronic Idiopathic Urticaria**

Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (FcεRI) on cells down-regulate. The mechanism by which these effects of omalizumab result in an improvement of CIU symptoms is unknown.

### Pharmacodynamics

## **Asthma**

In clinical studies in asthma patients, serum free IgE levels (i.e. unbound IgE) were reduced in a dose dependent manner within 1 hour following the first dose and maintained between doses. Mean serum free IgE decrease was greater than 96% using recommended doses. Serum total IgE levels (i.e., bound and unbound) increased after the first dose due to the formation of omalizumab:IgE complexes which have a slower elimination rate compared with free IgE. At 16 weeks after the first dose, average serum total IgE levels were five-fold higher compared with pre-treatment when using standard assays. After discontinuation of XOLAIR<sup>®</sup> dosing, the XOLAIR<sup>®</sup> induced increase in total IgE and decrease in free IgE were reversible with no observed rebound in IgE levels after drug washout. Total IgE levels returned to pre-treatment levels within one year after discontinuation of XOLAIR<sup>®</sup>.

## **Chronic Idiopathic Urticaria**

In clinical studies in CIU patients, omalizumab treatment led to a dose-dependent reduction of free IgE and an increase of total IgE levels in serum, similar to the observations in asthma patients. Maximum suppression of free IgE was observed 3 days after the first subcutaneous dose. After repeated dosing once every 4 weeks, pre-dose serum free IgE levels remained stable between 12 and 24 weeks of treatment. Total IgE levels in serum increased after the first dose due to the formation of omalizumab:IgE complexes which have a slower elimination rate compared with free IgE. After repeated dosing once every 4 weeks at 75 mg to 300 mg, average pre-dose serum total IgE levels at week 12 were two-to three-fold higher compared with pre-treatment levels, and remained stable between 12 and 24 weeks of treatment. After discontinuation of XOLAIR<sup>®</sup> dosing, free IgE levels increased and total IgE levels decreased towards pre-treatment levels over a 16-week treatment-free follow-up period.

## **Pharmacokinetics**

After SC administration, omalizumab is absorbed with an average absolute bioavailability of 62%. The pharmacokinetics of omalizumab are linear at doses greater than 0.5 mg/kg.

*In vitro*, omalizumab forms complexes of limited size with IgE. Precipitating complexes and complexes larger than 1 million daltons in molecular weight are not observed *in vitro* or *in vivo*. Tissue distribution studies in cynomolgus monkeys showed no specific uptake of <sup>125</sup>I-Omalizumab by any organ or tissue.

Clearance of omalizumab involves IgG clearance processes as well as clearance via specific binding and complex formation with its target ligand, IgE. Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile. In studies with mice and monkeys, omalizumab:IgE complexes were eliminated by interactions with Fcγ receptors within the RES at rates that were generally faster than IgG clearance.

## **Asthma**

Following a single SC dose in adult and adolescent patients with asthma, omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 7-8 days. Following multiple doses of omalizumab, areas under the serum concentration-time curve from Day 0 to Day 14 at steady state were up to 6-fold of those observed after the first dose.

The apparent volume of distribution of omalizumab in patients with asthma following SC administration was  $78 \pm 32$  mL/kg. In asthma patients omalizumab serum elimination half-life averaged 26 days, with apparent clearance averaging  $2.4 \pm 1.1$  mL/kg/day. Doubling body weight approximately doubled apparent clearance.

### **Chronic Idiopathic Urticaria**

Following a single subcutaneous dose in adult and adolescent patients with CIU, omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 6 to 8 days.

In patients with CIU, omalizumab exhibited linear pharmacokinetics across the dose range of 75 mg to 600 mg given as a single subcutaneous dose. Following doses of 75 mg, 150 mg or 300 mg every 4 weeks, trough serum concentrations of omalizumab increased proportionally with the dose level.

Based on population pharmacokinetic, distribution of omalizumab in CIU patients was similar to that in patients with asthma.

In patients with CIU, based on population pharmacokinetic simulations, omalizumab serum elimination half-life at steady state averaged 24 days and apparent clearance at steady state averaged 260 mL/day (corresponding to 3.3 mL/kg/day for an 80 kg patient).

### **Special Populations and Conditions**

#### **Asthma**

The population pharmacokinetics of XOLAIR<sup>®</sup> in asthma patients were analyzed to evaluate the effects of demographic characteristics. Analyses of these limited data suggest that no dose adjustments are necessary for age (12-76 years), race, ethnicity or gender.

#### **Chronic Idiopathic Urticaria**

The effects of demographic covariates and other factors on omalizumab exposure were evaluated using population pharmacokinetics. In addition, covariate effects were evaluated by analyzing the relationship between omalizumab concentrations and clinical responses. These analyses suggest that no dose adjustments are necessary in patients with CIU for age (12 to 75 years), race/ethnicity, gender, body weight, body mass index, baseline IgE, anti-FcεRI autoantibodies or concomitant use of H2 antihistamines or leukotriene receptor antagonists (LTRAs).

**Hepatic and Renal Insufficiency:** There have been no studies on the effect of impaired renal or hepatic function on the pharmacokinetics of XOLAIR<sup>®</sup>. Because omalizumab clearance at clinical doses is dominated by the reticular endothelial system (RES) it is unlikely to be altered by renal or hepatic impairment. While no particular dose adjustment is recommended, XOLAIR<sup>®</sup> should be administered with caution in these patients (see WARNINGS AND PRECAUTIONS).

**Genetic Polymorphism:** There have been no studies on the effect of genetic polymorphisms on the pharmacokinetics of XOLAIR<sup>®</sup>.

### **STORAGE AND STABILITY**

XOLAIR® (omalizumab) should be stored under refrigerated conditions 2°-8°C. Do not freeze. Do not use beyond the expiration date stamped on carton.

XOLAIR® is for single use only. It is recommended that XOLAIR® be used immediately following reconstitution (i.e. within 4 hours), as there is no preservative in the formulation. Physico-chemical stability studies have shown that the reconstituted product may be stored at 2°-8°C for up to 8 hours and for 4 hours at 30°C, if the recommended reconstitution procedures are followed.

Reconstituted XOLAIR® vials should be protected from direct sunlight.

### **DOSAGE FORMS, COMPOSITION AND PACKAGING**

XOLAIR® (omalizumab) is a sterile, white, preservative-free, lyophilized powder contained in a single-use 5-cc vial that is reconstituted with sterile water for injection (SWFI), USP, and administered as a subcutaneous (SC) injection. A XOLAIR® vial contains 202.5 mg of the active substance, omalizumab, and the following non-medicinal ingredients: 145.5 mg sucrose (0.5 calories or 2.3 Joules), 2.8 mg L-histidine hydrochloride monohydrate, 1.8 mg L-histidine and 0.5 mg polysorbate 20. It is designed to deliver 150 mg omalizumab, in 1.2 mL, after reconstitution with 1.4 mL SWFI, USP.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION

#### Drug Substance

Proper name: Omalizumab

Chemical name: Recombinant humanized monoclonal antibody-E25 (rhuMAb-E25)

Molecular/Structural formula:

The amino acid sequence for the two light chains is as follows:

```
1   DIQLTQSPSSLSASVGDRTITCRASQSVD
31  YDGDSYMNWYQQKPGKAPKLLIYAASYLES
61  GVPSRFSGSGSGTDFTLTISSLQPEDFATY
91  YCQQSHEDPYTFGQGTKVEIKRTVAAPSVF
121 IFPPSDEQLKSGTASVVCLLNNFYPREAKV
151 QWKVDNALQSGNSQESVTEQDSKDESTYSL
181 STLTLKADYEKHKVYACEVTHQGLSSPVT
211 KSFNRGEC
```

The amino acid sequence of the two heavy chains is as follows:

```
1   EVQLVESGGGLVQPGGSLRLSCAVSGYSIT
31  SGYSWNWIRQAPGKGLEWVASITYDGSTNY
61  NPSVKGRITISRDDSKNTFYLMNSLRAED
91  TAVYYCARGSHYFGHWHFAVWGQGTLLVTVS
121 SASTKGPSVFPLAPSSKSTSGGTAALGCLV
151 KDYFPEPVTVSWNSGALTSGVHTFPAVLQS
181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKP
211 SNTKVDKKVEPKSCDKTHTCPPCPAPELLG
241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDV
271 SHEDPEVKFNWYYDGVEVHNAKTKPREEQY

301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
331 ALPAPIEKTISKAKGQPREPQVYTLPPSRE
361 EMTKNQVSLTCLVKGFYPSDIAVEWESNGQ
391 PENNYKTTTPVLDSDGSFFLYSKLTVDKSR
421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPG
451 K
```

Molecular Mass: 149,170.6 Da.

Physicochemical properties: The mature rhuMAb-E25 molecule has two 218-residue light chains and two 450- or 451-residue heavy chains, with the 450-residue form predominating. Each light chain is disulfide-bonded to a heavy chain. Interchain disulfide bonds attach the heavy chains to each other. One N-linked glycosylation site is present in the heavy chain constant region at a position (Asn-301) that is conserved in all human IgG1 antibodies. rhuMAb-E25 has >99% glycosylation at a single conserved site (Asn-H301) in the CH2 domain.

## CLINICAL TRIALS

### Asthma

The safety and efficacy for XOLAIR<sup>®</sup> (omalizumab) were evaluated in four randomized, double-blind, placebo-controlled, multicenter trials (studies 1, 2, 3 and 4). Supplemental data from two open-label controlled studies in moderate to severe allergic asthma are also included (studies 5 and 6). XOLAIR<sup>®</sup> dosing was based on body weight and baseline serum total IgE concentration.

Studies 1 and 2 were of similar design and are presented together. The two trials enrolled 1,071 atopic patients 12 to 76 years old, with moderate to severe persistent (NHLBI criteria) asthma for at least one year with a positive skin test reaction to a perennial aeroallergen. Patients were non-smoking asthmatics requiring daily treatment with inhaled corticosteroids (beclomethasone dipropionate), 420 to 1,008 micrograms per day, and a beta-agonist as needed (maximum 8 puffs per day).

Studies 1 and 2 were designed to evaluate asthma exacerbations. At screening, patients in Studies 1 (n=525) and 2 (n=546) had a forced expiratory volume in one second (FEV<sub>1</sub>) between 40% and 80% predicted and were required to be symptomatic on entry. In both studies, entry criteria included demonstration of at least 12% improvement of FEV<sub>1</sub> following short acting beta agonist administration, concurrent treatment with inhaled corticosteroids (ICS) and short acting beta-agonists. Patients receiving other concomitant controller medications were excluded, as were current smokers. Initiation of additional controller medications while on study was prohibited.

Each study comprised a run-in period to achieve a stable conversion to a common ICS (beclomethasone dipropionate), followed by randomisation to XOLAIR<sup>®</sup> or placebo. In both studies, patients received XOLAIR<sup>®</sup> for 16 weeks with an unchanged ICS dose unless an acute exacerbation necessitated an increase. Patients then entered an ICS reduction phase of 12 weeks, during which ICS dose reduction was attempted in a step-wise manner.

In Studies 1 and 2 the distribution of the number of asthma exacerbations per patient in each group during the study was analysed separately for the stable steroid and steroid-reduction periods. The number of exacerbations was reduced in patients treated with XOLAIR<sup>®</sup> compared with placebo (Table 1).

**Table 1: Frequency of asthma exacerbations per patient in Studies 1 and 2**

		Stable Steroid phase (16 weeks)					
		Study 1		Study 2		Combined Studies 1 & 2	
		XOLAIR®	Placebo	XOLAIR®	Placebo	XOLAIR®	Placebo
		N = 268	N = 257	N = 274	N = 272	N = 542	N = 529
		(%)	(%)	(%)	(%)	(%)	(%)
Exacerbations per patient	≥ 1	14.6	23.3	12.8	30.5	13.7	26.9
P value		0.006 <sup>†</sup>		<0.001 <sup>†</sup>		<0.001 <sup>†</sup>	
Mean number of exacerbations per patient		0.28	0.54	0.28	0.66	0.28	0.6
		Steroid reduction phase (12 weeks)					
		Study 1		Study 2		Combined Studies 1 & 2	
		XOLAIR®	Placebo	XOLAIR®	Placebo	XOLAIR®	Placebo
		N = 268	N = 257	N = 274	N = 272	N = 542	N = 529
		(%)	(%)	(%)	(%)	(%)	(%)
Exacerbations per patient	≥ 1	21.3	32.3	15.7	29.8	18.5	31
P value		0.003 <sup>†</sup>		<0.001 <sup>†</sup>		<0.001 <sup>†</sup>	
Mean number of exacerbations per patient		0.39	0.66	0.36	0.75	0.38	0.71

<sup>†</sup> Van Elteren test

In both Studies 1 and 2, XOLAIR® was superior to placebo with respect to the primary variable of asthma exacerbation (defined as worsening of asthma requiring systemic corticosteroids or a doubling of the patient's baseline beclomethasone dose). The analysis of the number of asthma exacerbations favoured XOLAIR® over placebo during both the stable steroid periods and steroid sparing periods as shown in the table above.

In double-blind extension phases of both studies out to one year treatment the reduction in the frequency of asthma exacerbations for omalizumab treated patients compared to placebo-treated patients was maintained.

Results were also statistically significant in favour of XOLAIR® compared to placebo with respect to percent reduction in the dose of inhaled beclomethasone dipropionate and for the amount of rescue medication required. These results are presented in Table 2.

**Table 2: Number of puffs of rescue medication used (stabilization phase) and relative reduction in steroid usage (steroid-reduction phase)**

Variable	Study 1		Study 2	
	XOLAIR® (N=268)	Placebo (N=257)	XOLAIR® (N=274)	Placebo (N=272)
<i>Stable steroid phase</i>				
Median puffs of rescue medication per day and p-value	3.18	3.71	2.0	3.67
	p=0.029		p<0.001	
<i>Steroid reduction phase</i>				
Median absolute reduction	420 µg	336 µg	500 µg	300 µg
Median relative % reduction and p-value	75 %	50 %	83 %	50 %
	p<0.001		p<0.001	
% patients with 100 % reduction	40	19	43	20

Results from the stable steroid phase of Study 2 and the steroid reduction phases of both Studies 1 and 2 were similar to those presented in Table 3.

**Table 3: Asthma Symptoms and Pulmonary Function During Stable Steroid Phase of Study 1**

Endpoint	XOLAIR® N=268 <sup>a</sup>		Placebo N=257 <sup>a</sup>	
	Mean Baseline	Median Change (Baseline to Wk 16)	Mean Baseline	Median Change (Baseline to Wk 16)
Total asthma symptom score	4.3	-1.5 <sup>b</sup>	4.2	-1.1 <sup>b</sup>
Nocturnal asthma score	1.2	-0.4 <sup>b</sup>	1.1	-0.2 <sup>b</sup>
Daytime asthma score	2.3	-0.9 <sup>b</sup>	2.3	-0.6 <sup>b</sup>
FEV1 % predicted	68	3 <sup>b</sup>	68	0 <sup>b</sup>

Asthma symptom scale: total score from 0 (least) to 9 (most); nocturnal and daytime scores from 0 (least) to 4 (most symptoms).

<sup>a</sup> Number of patients available for analysis ranges 25-258 in the XOLAIR® group and 238-239 in the placebo group.

<sup>b</sup> Comparison of XOLAIR® versus placebo (p<0.05).

In the pivotal studies (Studies 1 and 2), XOLAIR<sup>®</sup> administration resulted in a substantial (6-fold) reduction in hospitalisations due to asthma exacerbations (13 vs 2 in the combined pivotal trials) and fewer premature discontinuations [60 (11.1%) vs 108 (20.4%) of patients] and discontinuations attributed to unsatisfactory therapeutic effect [5 (0.9%) vs 26 (4.9%) of patients].

In Studies 1 and 2, clinically meaningful improvement in asthma-related quality of life, measured by the validated Juniper's Asthma Quality of Life Questionnaire, was demonstrated in the XOLAIR<sup>®</sup> group at the end of the 28-week core trial compared to that observed in the placebo treated group (difference from placebo  $p \leq 0.001$  in Studies 1 and 2). The proportion of patients achieving a clinically meaningful improvement in Quality of Life i.e., demonstrating a  $\geq 0.5$  unit increase over the 28-week core trial, was 69% for the XOLAIR<sup>®</sup> group compared to 55% for the placebo group in study 1, and 67% for the XOLAIR<sup>®</sup> group compared to 57% for the placebo group in study 2 ( $p < 0.05$ ; Chi-squared test for each study separately).

In Study 3 the safety and corticosteroid sparing effect of omalizumab was demonstrated in 246 patients with severe allergic asthma requiring daily treatment with high-dose inhaled corticosteroids (fluticasone  $\geq 1000$  micrograms /day) and other concomitant asthma medications, including long acting beta 2-agonists. 246 patients were treated with high dose ICS and 95 patients treated with high dose ICS and oral steroids. The study included a 16-week steroid stable phase with study medication added, followed by a 16-week steroid reduction phase. Study 3 was specifically designed to evaluate steroid sparing effects rather than effect on asthma exacerbations. Efficacy was measured by a reduction in ICS use in the subpopulation of 246 patients treated with high dose ICS therapy.

The percent reduction in inhaled corticosteroid dose at the end of the treatment phase was significantly greater in omalizumab treated patients versus placebo patients (median 60% vs. 50%,  $p=0.003$ ). The proportion of omalizumab patients who were able to reduce their fluticasone dose by  $\geq 50\%$  was 73.83% versus 50.8% in the placebo group ( $p>0.001$ ).

In study 4 the safety and efficacy of omalizumab were demonstrated in 405 patients aged 12-75 years with co-morbid allergic asthma and perennial allergic rhinitis. Eligible patients had both symptomatic allergic asthma and perennial allergic rhinitis. Patients were treated with omalizumab or placebo for 28 weeks as add on therapy to  $\geq 400\mu\text{gs}$  of Budesonide Turbohaler. Inhaled long acting beta-2 agonists (39%) and nasal corticosteroids (17%) were allowed.

The co-primary endpoints for study 4 were the incidence of asthma exacerbations (worsening of asthma requiring systemic corticosteroids or a doubling of the patient's baseline budesonide dose) and the proportion of patients in each treatment group with a  $\geq 1.0$  improvement from baseline at the end of the treatment phase in both asthma and rhinitis specific quality of life assessments (Juniper Quality of Life Assessment). The results are presented in Table 4.

Patients treated with omalizumab had a significantly lower incidence of asthma exacerbations than patients receiving placebo (20.6% omalizumab vs 30.1% placebo,  $p=0.02$ ) and there was a significantly higher proportion of omalizumab treated than placebo patients that improved by  $\geq 1.0$  points in both asthma and rhinitis specific quality of life assessments (57.7% omalizumab vs 40.6% placebo,  $p < 0.001$ ).

The reduction in exacerbations and improvements of quality of life in omalizumab treated patients was seen in the context of statistically significant improvements in both rhinitis and asthma symptoms, and lung function, compared to placebo.

**Table 4: Asthma Exacerbations and Quality of Life in Study 4**

<b>Primary efficacy variable</b>	<b>Omalizumab N=209 n(%)</b>	<b>Placebo N=196 n(%)</b>	<b>p-value</b>
<b>Number of asthma exacerbation episode</b>			
0	166 (79.4)	137 (69.9)	0.0200
≥1	43 (20.6)	59 (30.1)	
<b>AQLQ and RQOL</b>			
Responder	120 (57.7)	78 (40.6)	0.0005
Non-responder	88 (42.3)	114 (59.4)	
Missing	1	4	
Responder = improvement of ≥ 1.0 on both AQLQ & RQOL questionnaires			

In Study 4, a significant improvement from baseline was observed in XOLAIR<sup>®</sup> treated patients compared to patients receiving placebo at study Endpoint in all 7 domains of the RQOL. A significant improvement at Study Endpoint in overall asthma-specific quality of life was observed in those patients administered XOLAIR<sup>®</sup> compared to patients receiving placebo.

Studies 5 and 6 were open-label controlled studies in moderate to severe allergic asthma, where exacerbation data were collected. Study 5 was conducted for 52 weeks in 312 adult and adolescent patients aged 12-75 years with poorly controlled allergic asthma, and was designed primarily as an efficacy study evaluating the number of asthma deterioration related incidents (ADRI) defined as a course of antibiotic; a course of oral corticosteroid; work/school missing days due to asthma; hospital stay due to asthma; unscheduled physician visit; and/or ER visit due to asthma. Patients received omalizumab as add-on to current asthma treatment (median dose of inhaled corticosteroids was 2000 micrograms/day, 78% were receiving a long acting beta 2-agonist) or current asthma treatment alone. Patients had to have at least one asthma-related hospitalization or emergency room visit and at least one additional course of oral corticosteroids due to asthma in the previous year.

In Study 5, treatment with omalizumab led to a 61% reduction in clinically significant asthma exacerbation rate ( $p < 0.001$ ) compared to current asthma therapy alone. This reduction in exacerbations was seen in the context of statistically significant improvements in asthma symptoms, lung function, rescue medication use, and Quality of Life.

Study 6 was an open-label study to evaluate the safety of subcutaneous omalizumab for 24 weeks in adult and adolescent patients (aged 6 to 75 years) with predominantly severe persistent asthma already treated with other therapies (ALTO). Eligible patients had moderate to severe persistent asthma and were treated for at least 30 days prior to screening with moderate daily doses of inhaled corticosteroids and/ or stable daily doses of oral corticosteroids with at least one of the following: long-acting  $\beta$ -adrenergic (salmeterol), leukotriene receptor antagonist (LTRA), xanthine derivatives, or sodium cromoglycate. Patients were randomized (2:1 ratio) to either active treatment or the control group. Treatment was given in combination with ongoing asthma treatment.

A total of 1899 patients were randomized and treated during the study including 1262 omalizumab and 637 control patients. Although primarily undertaken to evaluate safety, efficacy was assessed by the incidence of protocol-defined asthma exacerbation episodes during the treatment phase and nocturnal symptoms as measured by the modified Inner City Asthma Study Morbidity Assessment (Mitchell et al 1997). Patients treated with omalizumab experienced 21% fewer protocol-defined asthma exacerbations (95% CI: 0.62, 0.99), 35% fewer asthma exacerbations resulting in hospitalizations (95% CI: 0.34, 1.22), 21% fewer asthma exacerbations resulting in ER visits (95% CI: 0.43, 1.54) and 20% fewer asthma exacerbations resulting in urgent medical visits (95% CI: 0.62, 1.03) compared with patients in the control group. Omalizumab patients had statistically significant reductions in nocturnal asthma symptoms ( $p < 0.001$  at Weeks 4, 12 and 24) and overall asthma symptoms ( $p < 0.05$ ) compared to the control group.

Throughout the clinical development program, all studies required that patients be treated with ICS at entry. In addition, several clinical studies (4,5,6) evaluated the safety and efficacy of XOLAIR<sup>®</sup> when concomitantly administered to other commonly used asthma medications (including inhaled and oral corticosteroids, inhaled short-acting and long-acting beta agonists, leukotriene modifiers, theophyllines and oral antihistamines). There was no indication that the addition of XOLAIR<sup>®</sup> altered the safety profile of these other commonly used asthma medications. Limited data are available on the use of XOLAIR<sup>®</sup> in combination with specific immunotherapy (hypo-sensitisation therapy).

A Poisson regression was used to investigate the effect of omalizumab treatment on asthma exacerbation rates in patients receiving concomitant LABAs compared to those patients not receiving concomitant LABAs (Table 5). None of these studies were designed to evaluate the subpopulation with and without LABA separately or make direct comparisons, however, a consistent numerical benefit is observed for patients treated with omalizumab versus placebo in these analyses.

**Table 5: Clinically significant exacerbations for XOLAIR® versus placebo in patients with LABA and without LABA use\***

LABA use	Treatment	n	Number with no exacerbations	Number experiencing 1 or more exacerbations	Rate per period	Rate ratio (95% CI)
<b>Study 4 (28 weeks)</b>						
Yes	XOLAIR®	86	68	18	0.35	0.615 (0.325 , 1.163)
	Placebo	71	46	25	0.58	
No	XOLAIR®	123	98	25	0.25	0.621 (0.364 , 1.062)
	Placebo	125	91	34	0.40	
<b>Study 5 (52 weeks)</b>						
Yes	XOLAIR®	167	78	89	1.05	0.425 (0.310 , 0.582)
	Control	84	20	64	2.47	
No	XOLAIR®	39	24	15	0.67	0.272 (0.115 , 0.641)
	Control	22	8	14	2.47	
<b>Study 6 (≥12 year olds, 24 weeks)</b>						
Yes	XOLAIR®	994	681	343	0.48	0.863 (0.707 , 1.052)
	Control	500	325	175	0.55	
No	XOLAIR®	175	109	66	0.42	0.747 (0.459 , 1.218)
	Control	91	59	32	0.56	

\* Based on Poisson models including terms for LABA use

### Overall impact of XOLAIR® administration on Quality of Life

With the exception of Study 6, which did not measure Quality of life, all the studies prospectively collected data on patient's asthma-specific quality of life by using the validated Juniper's Asthma Quality of Life Questionnaire. XOLAIR® provided statistically and clinically meaningful greater improvement in asthma-specific quality of life over placebo. Improvements were demonstrated in all four asthma-specific domains of the Asthma Quality of Life Questionnaire, i.e., activities, symptoms, emotional function and environmental exposure as well as in the overall score. A summary of the proportion of patients achieving a clinically meaningful improvement in the AQLQ is included in Table 6 below.

**Table 6: Clinically meaningful improvement in quality of life (Juniper AQLQ Change from baseline  $\geq 0.5$ )**

Study number	Omalizumab %	Placebo/Control %	p-value
<b>1 (28 weeks)</b>	66	55	<0.05
<b>2 (28 weeks)</b>	67	57	<0.05
<b>3 (32 weeks)</b>	52.3	35.7	0.004
<b>4 (28 weeks)</b>	78.8	69.8	0.002
<b>5 (32 weeks)</b>	71.8	43.2	<0.001

### **Chronic Idiopathic Urticaria (CIU)**

The clinical Phase III development program for CIU (also referred in some studies as Chronic Spontaneous Urticaria – CSU) included two randomized, double-blind, placebo controlled, parallel-group, multi-center studies: ASTERIA I (Q4881g) and ASTERIA II (Q4882g). ASTERIA I and ASTERIA II studies evaluated efficacy and safety of administration of 75 mg, 150 mg, or 300 mg XOLAIR<sup>®</sup> every 4 weeks for 24 and 12 weeks respectively, with a 16-Week treatment free follow-up period in patients (12-75 years) with refractory CIU despite H1 antihistamine treatment as per approved dosage.

Disease severity was measured by a weekly urticaria activity score (UAS7, range 0–42), which is a composite of the weekly itch severity score (range 0–21) and the weekly number of hive score (range 0–21). In the two studies, the primary endpoint was the change from baseline to Week 12 in weekly itch severity score.

The mean weekly itch severity scores at baseline were balanced across treatment groups and ranged between 13.7 and 14.5 despite use of an H1 antihistamine at a recommended dose.

In both ASTERIA I and ASTERIA II Studies, patients who received XOLAIR<sup>®</sup> 150 mg or 300 mg had greater decreases from baseline in weekly itch severity scores, weekly number of hive scores than placebo at Week 12 (Table 7 and Table 8). The 75 mg dose did not demonstrate consistent evidence of efficacy and is not considered an efficacious dose.

**Table 7: Summary of clinical outcomes at Week 12 in ASTERIA I study (mITT population<sup>‡</sup>)**

	XOLAIR <sup>®</sup> 75mg (n = 77)	XOLAIR <sup>®</sup> 150mg (n = 80)	XOLAIR <sup>®</sup> 300mg (n = 81)	Placebo (n = 80)
<b>Weekly Itch Severity Score<sup>a</sup></b>				
Mean Baseline Score (SD)	14.5 (3.6)	14.1 (3.8)	14.2 (3.3)	14.4 (3.5)
Mean Change Week 12 (SD)	-6.46 (6.14)	-6.66 (6.28)	-9.40 (5.73)	-3.63 (5.22)
Treatment Difference in LS Means* relative to the Placebo	-2.96	-2.95	-5.80	-
95% CI of the LS Mean difference relative to Placebo	-4.71, -1.21	-4.72, -1.18	-7.49, -4.10	-
p-value <sup>§</sup>	0.0010	0.0012	<0.0001	-
<b>Weekly Number of Hives Score</b>				
Mean Baseline Score (SD)	17.2 (4.2)	16.2 (4.6)	17.1 (3.8)	16.7 (4.4)
Mean Change Week 12 (SD)	-7.36 (7.52)	-7.78 (7.08)	-11.35 (7.25)	-4.37 (6.60)
<b>Proportion of patients with UAS7 ≤ 6 at Week 12</b> n (%)	20 (26.0%)	32 (40.0%)	42 (51.9%)	9 (11.3%)
<b>Proportion of patients with UAS7 =0 (no itch and no hives) at Week 12, n (%)</b>	9 (11.7%)	12 (15.0%)	29 (35.8%)	7 (8.8%)

<sup>‡</sup> Modified intent-to-treat (mITT) population: patients who were randomized and received at least one dose of study medication.

\*The LS mean was estimated using an ANCOVA model. The strata were baseline weekly itch severity score (< 13 vs. ≥13) and baseline weight (< 80 kg vs. ≥ 80 kg).

<sup>§</sup> p-value is derived from ANCOVA t-test.

- The testing strategy for the primary endpoint controlled the overall type I error rate of 0.05 across the three omalizumab doses.

- BOCF (Baseline Observation Carried Forward) was used to impute missing data for the endpoints of weekly itch severity score and number of hives score at week 12

-Patients were classified as UAS7>6 or a non-responder at week 12 if they had a missing value of UAS7 at week 12

**Table 8: Summary of clinical outcomes at Week 12 in ASTERIA II study (mITT population<sup>‡</sup>)**

	XOLAIR <sup>®</sup> 75mg (n = 82)	XOLAIR <sup>®</sup> 150mg (n = 82)	XOLAIR <sup>®</sup> 300mg (n = 79)	Placebo (n = 79)
<b>Weekly Itch Severity Score<sup>a</sup></b>				
Mean Baseline Score (SD)	14.0 (3.7)	14.2 (4.1)	13.7 (3.5)	14.0 (3.4)
Mean Change Week 12 (SD)	-5.87 (6.45)	-8.14 (6.44)	-9.77 (5.95)	-5.14 (5.58)
Treatment Difference in LS Means* relative to the Placebo	-0.69	-3.04	-4.81	-
95% CI of the LS Mean difference relative to Placebo	2.54, 1.16	-4.85, -1.24	-6.49, -3.13	-
p-value <sup>§</sup>	0.4637	0.0011	<0.0001	-

<b>Weekly Number of Hives Score</b>				
Mean Baseline Score (SD)	16.8 (4.2)	17.1 (4.1)	15.8 (4.6)	17.0 (4.2)
Mean Change Week 12 (SD)	-7.21 (6.96)	-9.75 (7.28)	-11.97 (7.58)	-5.22 (6.56)
<b>Proportion of patients with UAS7 ≤ 6 at Week 12</b> n (%)	22 (26.8%)	35 (42.7%)	52 (65.8%)	15 (19.0%)
<b>Proportion of patients with UAS7 =0 (no itch and no hives) at Week 12, n (%)</b>	13 (15.9%)	18 (22.0%)	35 (44.3%)	4 (5.1%)

\* Modified intent-to-treat (mITT) population: patients who were randomized and received at least one dose of study medication.

\*The LS mean was estimated using an ANCOVA model. The strata were baseline weekly itch severity score (< 13 vs. ≥13) and baseline weight (< 80 kg vs. ≥ 80 kg).

§ p-value is derived from ANCOVA t-test.

- The testing strategy for the primary endpoint controlled the overall type I error rate of 0.05 across the three omalizumab doses.

- BOCF (Baseline Observation Carried Forward) was used to impute missing data for the endpoints of weekly itch severity score and number of hives score at week 12


-Patients were classified as UAS7>6 or a non-responder at week 12 if they had a missing value of UAS7 at week 12

### Response over time

In both ASTERIA I and ASTERIA II, the mean weekly itch severity scores significantly decreased in both treatment groups with a maximum effect around week 12. In the two studies, the mean weekly itch severity score for both doses increased gradually during the 16-Week treatment-free follow-up period. Mean values at the end of the follow-up period were similar to the placebo group, but lower than the respective baseline values.

The mean weekly itch severity score at each study week by treatment groups is shown in Figure 1. Representative results from ASTERIA I are shown; similar results were observed in ASTERIA II.

**Figure 1: Mean Weekly Itch Severity Score by Treatment Group in ASTERIA I (mITT population<sup>‡</sup>)**



<sup>‡</sup> Modified intent-to-treat (mITT) population: patients who were randomized and received at least one dose of study medication.  
 - BOCF (Baseline Observation Carried Forward) was used to impute missing data

### Other Clinical Trials

A third study, GLACIAL, primarily evaluated the safety of XOLAIR<sup>®</sup> 300 mg in patients with refractory CIU despite H1 antihistamines. The mean decrease from baseline to Week 12 in weekly itch severity score (the primary endpoint in ASTERIA I and ASTERIA II) was 4.01 in the placebo group and 8.55 in the XOLAIR<sup>®</sup> group. The other efficacy endpoints in the study were those used as secondary endpoints in ASTERIA I. The magnitude of differences to placebo was consistent with those observed in ASTERIA I and ASTERIA II.

## DETAILED PHARMACOLOGY

### ANIMAL PHARMACOLOGY

Omalizumab is characterized as a non-anaphylactogenic antibody because of the following: Epitope mapping studies demonstrated that omalizumab and MaE11 bind the same site on IgE as FcεRI; omalizumab did not recognize IgE on FcεRI-bearing cells; omalizumab did not induce spontaneous histamine release from IgE-loaded human basophils.

With the exception of one possibly drug-related anaphylactoid reaction in a patient, omalizumab administration did not result in anaphylaxis in nonhuman primates or in the clinic.

Characterization of omalizumab:IgE complexes demonstrated that: omalizumab forms complexes with IgE that are predominantly heterotrimers or hexamers with a maximum molecular weight of 1 million; the size and composition of the complex is dependent on the molar ratio of the 2 molecules. Complexes formed *in vivo* were similar to those studied *in vitro*. Neither omalizumab nor omalizumab:IgE complexes bound C1q or generated C3a. omalizumab did not mediate complement-dependent cytotoxicity. No evidence of immune complex disease has been observed in the nonclinical or clinical setting after administration of omalizumab.

Binding studies showed that omalizumab bound human IgE with high affinity. omalizumab bound cynomolgus IgE with similar affinity, supporting the selection of this species for further nonclinical pharmacology and toxicology studies.

Characterization of omalizumab as an inhibitor of IgE:FcεRI interaction demonstrated that omalizumab competitively inhibited IgE:FcεRI interaction, consistent with the epitope mapping of omalizumab and FcεRI to the same site on IgE. omalizumab was able to trap IgE as it dissociated from the FcεRI *in vitro* and may, therefore, aid in off-loading IgE from receptors *in vivo*.

Omalizumab was able to suppress very high levels of total free IgE to 25 ng/mL, the therapeutic target identified in clinical studies, at molar ratios of omalizumab:IgE ranging from 16 to 21. omalizumab inhibited histamine release from cells sensitized with ragweed-specific IgE. omalizumab also blocked histamine release and contraction of human and cynomolgus monkey lung strips after passive sensitization with ragweed-specific IgE.

Omalizumab reduced high-affinity receptor expression *in vitro* and *in vivo* by decreasing free IgE. Treatment with omalizumab reduced FcεRI on human basophils such that histamine release was reduced or eliminated in response to antigen challenge.

Omalizumab inhibited IgE synthesis *in vitro*; however, no significant effect on IgE synthesis was observed clinically. There are no data to suggest that administration of omalizumab and the resultant decreased levels of free IgE cause a positive feedback signal and increased synthesis of IgE when omalizumab therapy is withdrawn.

Omalizumab demonstrated pharmacological activity in a nonhuman primate model of hypersensitivity to ragweed. Skin test reactivity was reduced in cynomolgus monkeys sensitized to ragweed after administration of omalizumab.

## TOXICOLOGY

A comprehensive series of toxicology studies was conducted to establish a nonclinical safety profile.

Since omalizumab does not bind to mouse IgE, and IgE is not normally found in mouse serum at significant levels, the mouse was selected to evaluate high dose nonspecific toxicity. The cynomolgus monkey was considered to be a relevant species for preclinical toxicity evaluations because omalizumab has nearly equivalent affinity for IgE purified from cynomolgus monkey serum (0.19 nM) as for human IgE (0.06 nM). In addition, the monkey is considered an exaggerated model of atopy compared with humans as baseline serum concentrations of IgE were generally greater in cynomolgus monkeys than normally observed in the atopic individuals enrolled in our clinical trials. Consequently, the monkeys in these studies had much higher levels of omalizumab:IgE complexes than would be expected in typical humans with asthma.

This comprehensive series of acute and multiple-dose toxicity studies demonstrated that omalizumab produced no adverse effects at clinically relevant serum concentrations of drug. At suprapharmacologic serum concentrations, dose levels of up to 250 mg/kg (more than 14-fold the maximum allowable clinical dose), omalizumab induced thrombocytopenia and effects secondary to thrombocytopenia. The serum concentration required to attain a 50% drop in platelets from baseline was roughly 3.7 to 20-fold higher than anticipated serum concentrations in adult and adolescent clinical patients receiving the highest dose of omalizumab. Other than the platelet-associated effects observed at suprapharmacologic doses, there were no other clinical or pathological signs of toxicity. In particular, no clinical or histopathological evidence of renal toxicity nor evidence of a systemic anaphylactic response due to mast cell degranulation were observed in any of the studies, despite the presence of omalizumab:IgE complexes in all of the monkey studies.

Omalizumab has been shown to evoke a low level immune response to heterologous protein in some cynomolgus monkeys. This is not unexpected based on administration of a heterologous protein. Special toxicity studies demonstrated safety in a cynomolgus monkey model challenged with ragweed allergen, no evidence of in vitro tissue cross-reactivity with cynomolgus monkey and human tissues, no evidence of in vitro hemolysis of human and cynomolgus monkey erythrocytes or incompatibility with human and cynomolgus monkey serum and plasma, and no evidence of irritation in the rabbit. In addition, omalizumab was not mutagenic in the Ames test. No rodent carcinogenicity studies have been performed since omalizumab does not bind rodent IgE and the IgG structure of omalizumab does not raise any concerns relating to carcinogenic potential. Reproduction studies in cynomolgus monkeys have been conducted with Omalizumab. Subcutaneous doses up to 75 mg/kg (10-fold the highest recommended clinical dose in mg/kg over a 4-week period) of Omalizumab did not elicit maternal toxicity, embryotoxicity, or teratogenicity when administered throughout organogenesis and did not elicit adverse effects on fetal or neonatal growth when administered throughout late gestation, delivery, and nursing. Although no clinically significant effects on platelets have been observed in patients, doses of omalizumab in excess of the clinical dose have been associated with age-dependent decreases in blood platelets in nonhuman primates, with a greater relative sensitivity in juvenile animals. In reproduction studies in cynomolgus monkeys, there was no clinical evidence of thrombocytopenia in neonatal monkeys from mothers treated with up to 75 mg/kg

omalizumab; however, platelet counts were not measured in these offspring. The excretion of omalizumab in milk was evaluated in female cynomolgus monkeys receiving SC doses of 75 mg/kg/week. Neonatal serum levels of omalizumab after *in utero* exposure and 28 days of nursing were between 11% and 94% of the maternal serum level. Milk levels of omalizumab were 0.15% of the maternal serum concentration.

### Acute Toxicity Studies

Study Type	Species/ Strain	No./Sex/ Group	Route of Admin. <sup>a</sup>	Dose (mg/kg)	Study Duration	Findings
Mouse/ single dose	Mouse Crl:CD-1 <sup>7</sup> (ICR) BR VAF/Plus <sup>7</sup>	5/M 5/F	IV	0 1 10 100	2 weeks	No test material-related clinical or pathological signs of toxicity were observed. With the exception of 2 animals in the mid-dose group, there was no evidence of antibody formation
Monkey/ single dose	Cynomolgus monkey	2/M 2/F	IV	0 0.5 5 50	2 weeks	No test material-related clinical signs of toxicity were observed. Free IgE and total IgE serum concentrations at baseline and Day 15 were similar for control and low-dose. From baseline to Day 15, the total serum IgE in the mid- and high-dose groups increased in all animals, whereas the free serum IgE either decreased or did not increase. There was no evidence of antibody formation. rhuMAb E25 at a dose of 1 µg did not elicit an allergic response when injected intradermally on Day 15.
Monkey/ single dose	Cynomolgus monkey	2/M 2/F	SC	0 0.5 5	2 weeks	No test material-related clinical signs of toxicity were observed. Free IgE and total IgE serum concentrations at baseline and Day 15 were similar for control and low-dose groups. From baseline to Day 15, the total serum IgE in the mid- and high-dose increased in all animals, whereas the free serum IgE either decreased or did not increase. There was no evidence of antibody formation. rhuMAb E25 at a dose of 1 µg did not elicit an allergic response when injected intradermally on Day 15.
Monkey/ single dose (bridging)	Cynomolgus monkey	2/M 2/F	IV  SC	0 50 200 50	2 weeks <sup>b</sup>	A single intravenous dose of rhuMAb E25 up to 200 mg/kg or a single subcutaneous dose of rhuMAb E25 up to 50 mg/kg was well tolerated and produced no adverse effects in cynomolgus monkeys. Serum total IgE concentrations increased an average of 4-fold above baseline and free IgE decreased following rhuMAb E25 administration. Two animals in the high dose IV group had antibody titers to rhuMAb E25 Fab and one animal given SC rhuMAb E25 had a detectable anti-Fab titer.

<sup>a</sup> IV = Intravenous, SC = Subcutaneous.

<sup>b</sup> In addition to the 14 day postdose observation period; samples were collected 61 days postdose, to further evaluate antibody production to omalizumab.

### Repeated-Dose Toxicity Studies

Study Type	Species/ Strain	No./Sex/ Group	Route of Admin. <sup>a</sup>	Dose (mg/kg)	Study Duration	Findings
Mouse/ Multi-dose 4 Weeks	Mouse CrI:CD-1 <sup>7</sup> (ICR) BR/ VAF Plus <sup>7</sup>	15-25/M 15-25/F	IV	0 1 10 50	4 weeks dosing/ 4 weeks post obs	No test material-related clinical or pathological signs of toxicity were observed. There was no evidence of antibody formation to rhuMAb E25.
Monkey Multi-dose 4 Weeks	Cynomolgus monkey	1-5/M 1-5/F	IV SC	0 0.1 1 5 mg/kg 3 times per week	4 weeks dosing/ 4 weeks post obs	No test material-related clinical or pathological signs of toxicity were observed. rhuMAb E25 was eliminated slowly from serum; PK was linear. There was no significant difference in total serum IgE in low-dose as compared to control. Total serum IgE increased following treatment with mid- and high-doses of rhuMAb E25. Free serum IgE decreased or remained at baseline in control and low-dose animals, and decreased to undetectable amounts in mid- and high-dose animals. There was a low incidence (3/20 evaluated) of antibody formation to rhuMAb E25. rhuMAb E25 at a dose of 1 µg did not elicit an allergic response when injected intradermally at the end of the treatment period and at the end of the recovery period.
Monkey/ Multi-dose 6 months	Cynomolgus monkey	1-5/M 1-5/F	IV SC	0 0.1 1 5 mg/kg 3 times per week	26	Based on the results of this study, subcutaneous and intravenous bolus injections of rhuMAb E25 up to 5.0 mg/kg three times/week were well tolerated and produced no systemic adverse effects when administered to cynomolgus monkeys for approximately 6 months followed by an 8-week recovery. Serum total IgE concentrations increased approximately 6-fold compared to baseline in the high dose groups. There was a low incidence of antibody formation against rhuMAb E25.

<sup>a</sup> IV = Intravenous, SC = Subcutaneous.

**Repeated-Dose Toxicity Studies (continued)**

<b>Study Type</b>	<b>Species/ Strain</b>	<b>No./Sex/ Group</b>	<b>Route of Admin.<sup>a</sup></b>	<b>Dose (mg/kg)</b>	<b>Study Duration</b>	<b>Findings</b>
Monkey/ Multi-dose 6-months	Juvenile Cynomolgus monkey	4-6/M 4-6/F	SC	0 50 250 mg/kg/ week	26 weeks dosing/ 26 weeks recovery	Significant and sustained decreases in peripheral blood platelets were observed in juvenile cynomolgus monkeys following treatment with omalizumab. Effects were highly correlated to dose and serum concentration. Other than suppression of platelet levels and changes secondary to thrombocytopenia, no test-article-related effects were evident.
Monkey Multi-dose Up to 6-months	Juvenile and adult Cynomolgus monkeys	3-6/M 3-6/F	SC	0 15 30 50 100 250 mg/kg/ week	4, 6, or 26 weeks dosing/ 13 weeks recovery	Significant and sustained decreases in peripheral blood platelets were observed in cynomolgus monkeys following treatment with omalizumab. Effects were correlated to dose and serum concentration. The time of onset was earlier and the magnitude of severity was greater in juveniles than in adults.
Monkey Multi-dose 4-weeks with IVIG	Juvenile Cynomolgus monkey	3F	SC	0 100 100 with IVIG infusion on days 17 and 18	4 weeks dosing	Omalizumab at doses of 100mg/kg/week induced a moderate decrease in peripheral blood platelets in 3 of 6 cynomolgus monkeys that could be reversed by administration of IVIG (intravenous immunoglobulin). Given the inhibitory effect of IVIG on Fc-mediated clearance of platelets, it is likely that platelet phagocytosis plays a role in omalizumab-induced thrombocytopenia.
Monkey Multi-dose 12-weeks	Adult African green, cynomolgus, rhesus	3F	SC	0 100 250 mg/kg/ week	12-weeks dosing/ 13 weeks recovery	Significant and sustained decreases in peripheral blood platelets were observed in cynomolgus monkeys following treatment with omalizumab. The magnitude and persistence of decreased platelets was less pronounced in the rhesus and African green monkeys.

<sup>a</sup> SC = Subcutaneous.

**Repeated-Dose Toxicity Studies (continued)**

<b>Study Type</b>	<b>Species/ Strain</b>	<b>No./Sex/ Group</b>	<b>Route of Admin.<sup>a</sup></b>	<b>Dose (mg/kg)</b>	<b>Study Duration</b>	<b>Findings</b>
Multi-dose Up to 4-weeks	Chimpanzee	3M/3F	SC	250 mg/kg/ week	Up to 4-weeks dosing/ 13-weeks recovery	Omalizumab induces significant but reversible decreases in peripheral blood platelet counts at a dose of 250 mg/kg/week in the chimpanzee.

<sup>a</sup> SC = Subcutaneous.

**Reproductive Toxicity Studies**

<b>Study Type</b>	<b>Species/ Strain</b>	<b>No./Sex/ Group</b>	<b>Route of Admin.<sup>a</sup></b>	<b>Dose (mg/kg)</b>	<b>Study Duration</b>	<b>Findings</b>
Male Fertility Study	Cynomolgus monkey	10/M	SC	0 3 15 75	6 weeks dosing/ 2 weeks post obs	Subcutaneous administration of rhuMAb E25, at doses up to and including 75 mg/kg, was well tolerated and did not elicit reproductive toxicity in male cynomolgus monkey.
Female fertility study	Cynomolgus monkey	10/F	SC	0 3 15 75	4-5 months dosing	Subcutaneous administration of rhuMAb E25, at doses up to and including 75 mg/kg, was well tolerated and did not inhibit reproductive capacity, including implantation in female cynomolgus monkey.
Embryo- toxicity Terato- genicity	Cynomolgus monkey	12/F	SC	0 3 15 75	30 days dosing/ 50 days post obs	Subcutaneous administration of rhuMAb E25, at doses up to and including 75 mg/kg, was well tolerated and did not elicit maternal toxicity, embryotoxicity or teratogenicity when administered throughout organogenesis (gestation days 20-50) in the cynomolgus monkey.

<sup>a</sup> SC = Subcutaneous.

**Reproductive Toxicity Studies (continued)**

Study Type	Species/ Strain	No./Sex/ Group	Route of Admin. <sup>a</sup>	Dose (mg/kg)	Study Duration	Findings
Late gestation Study	Cynomolgus monkey	8/F	SC	0 75	30-70 days dosing	Subcutaneous administration of rhuMAb E25, at doses of 75 mg/kg, was well tolerated and did not elicit adverse effects on fetal growth at late gestation (gestation days 120 - delivery), delivery, nursing, or neonatal growth in the cynomolgus monkey.

<sup>a</sup> SC = Subcutaneous.

**Special Toxicity Studies**

Study Type	Species/ Strain	No./ Sex/ Group	Route of Admin. <sup>a</sup>	Dose (mg/kg)	Study Duration	Findings
Pilot evaluation in monkeys exposed to ragweed allergen	Cynomolgus monkeys	6/F	IV, SC	5 10 50	35 weeks	Skin sensitivity to ragweed was elicited in all animals after three challenge doses. Intradermal skin sensitivity was diminished after treatment with rhuMAb E25 and reactivity to ragweed returned approximately 55 days after rhuMAb E25 treatment was terminated. Subcutaneous doses of rhuMAb E25 up to 10 mg/kg and intravenous doses up to 50 mg/kg were well tolerated and produced no adverse effects in ragweed allergen sensitized cynomolgus monkeys.
Skin reactivity to ragweed extract/pilot evaluation	Cynomolgus monkey	2/F	ID (ragweed extract) IV (Evans Blue dye)	0.001, 0.01, 0.1, 1.0 µg	31 minutes	Based on the results of a wheal/flare allergy test aided with the use of Evans Blue, an allergic response was not elicited to ragweed when injected intradermally in naïve cynomolgus monkeys. A positive histamine response was elicited.
Tissue specificity analysis	Frozen cynomolgus monkey tissues	-	-	49 (rhuMA b E25)  22.5 (MaE11)	-	Specific staining was observed with both rhuMAb E25 and MaE11 in germinal centers of a lymph node and Peyer's patch of the large intestine of the female but not the male monkey. The reaction was considered to represent synthesis of IgE by lymphoid cells. Specific staining of other tissues was not observed.

<sup>a</sup> IV = Intravenous, SC = Subcutaneous, ID = Intradermal.

**Special Toxicity Studies cont=d**

<b>Study Type</b>	<b>Species/ Strain</b>	<b>No./ Sex/ Group</b>	<b>Route of Admin.<sup>a</sup></b>	<b>Dose (mg/kg)</b>	<b>Study Duration</b>	<b>Findings</b>
Tissue specificity analysis	Frozen human tissues	–	–	49 (rhuMAb E25) 22.5 (MaE11)	–	Specific staining of the tissues was not observed with rhuMAb E25 but was seen with MaE11. With the latter, reactivity was seen in lymphoid cells of 1/3 spleens. The reaction was considered to represent synthesis of IgE by lymphoid cells of that individual. Specific staining of other tissues was not observed.
In vitro hemolytic potential and blood compatibility	Human and cynomolgus monkey-whole blood, serum, plasma	–	–	0, 5	–	Results indicate that rhuMAb E25 and rhuMAb E25 Vehicle did not cause hemolysis of cynomolgus monkey or human erythrocytes and were compatible with cynomolgus monkey or human serum and plasma.
In vitro hemolytic potential and blood compatibility	Human and cynomolgus monkey - whole blood, serum, and plasma	–	–	0, 40	–	Results indicate that rhuMAb E25 (12,000 L; 40 mg/mL in formulation) and rhuMAb E25 (12,000 L) Vehicle did not cause hemolysis of of cynomolgus monkey or human erythrocytes and were compatible with cynomolgus monkey or human serum and plasma.
In vitro hemolytic potential and blood compatibility	Human whole blood, serum, and plasma	–	–	0, 100	–	Results indicate that rhuMAb E25 (lyophilized formulation) at a concentration of 100 mg/mL, and rhuMAb E25 Vehicle did not cause hemolysis of human erythrocytes and were compatible with human serum and plasma.
Acute local tolerance	Rabbit Hra: (NZW) SPF	9/M	IV SC ID	0, 5	1 week	No clinical observations or histopathological findings indicative of local irritation were attributed to the test material or vehicle.

<sup>a</sup> IV = Intravenous, SC = Subcutaneous, ID = Intradermal

**Special Toxicity Studies cont=d**

<b>Study Type</b>	<b>Species/ Strain</b>	<b>No./ Sex/ Group</b>	<b>Route of Admin.<sup>a</sup></b>	<b>Dose (mg/kg)</b>	<b>Study Duration</b>	<b>Findings</b>
Multiple dose SC single dose intravenous rabbit tolerance	Rabbit Hra: (NZW) SPF	15/M	IV, SC	0, 5, 20, 40	21 Days	Based on the results of this study, 14 daily subcutaneous injections (1 mL volume) of 5 mg/mL rhuMAb E25 (400 L) or 20 and 40 mg/mL of rhuMAb E25 (12,000 L) were associated with a slightly higher level of subacute inflammation at the injection sites than similar treatment in animals given the vehicles or saline. This inflammation was typically associated with an increased number of eosinophils. Because clinical signs of irritation were not evident beyond Day 12 and because the microscopic findings were not indicative of functional tissue damage, these findings were not considered toxicologically significant. There were no meaningful differences in incidence or severity of local irritation from rhuMAb E25 (12,000 L) when compared to rhuMAb E25 (400 L). There was no macroscopic or microscopic evidence of irritation following a single intravenous injection of 20 mg/mL of rhuMAb E25 (12,000 L) to rabbits.
Acute local tolerance	Rabbit Hra: (NZW) SPF	9/M	IV, SC	0, 100	1 week	Based on the results of this study, administration of rhuMAb E25 given as a single intravenous bolus injection and a single subcutaneous injection following reconstitution with 1.1% benzyl alcohol to a concentration of 100 mg/mL was well tolerated in rabbits and produced no obvious local irritation attributable to the test material.
Acute local tolerance	Rabbit Hra:(NZW)	3/F	SC	0, 125	1 week	Administration of rhuMAb E25 placebo and rhuMAb E25 as a single, 125 mg/mL subcutaneous bolus injection had no obvious irritating effect. Reconstituting the test material and placebo in saline, as opposed to sterile Water for Injection (SWFI) did not produce any differences in redness or swelling at the injection sites. Based on the results of this study, administration of rhuMAb E25 placebo and rhuMAb E25 given as a single subcutaneous bolus injection following reconstitution with either SWFI or saline to a concentration of 125 mg/mL was well tolerated in rabbits and produced no treatment-related signs of local irritation.

<sup>a</sup> IV = Intravenous,

SC = Subcutaneous,

ID = Intraderm

## REFERENCES

1. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM. Humanization of an antibody directed against IgE. *J Immunol* 1993; 151:2623-32
2. Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. *Cur Opin Immunol* 1997; 9:805-13.
3. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulations of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. *J Immunol* 1997; 158:1438-45
4. Saini SS, MacGlashan DW Jr, Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, et al. Down-regulation of human basophil IgE and FcεRIα surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. *J Immunol* 1999; 162:5624-30.
5. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. *Biochemistry* 1995; 34:10474-82.
6. Fox JA, Reitz B, Hagler K, Hsei V, Keller G, Ryan A. Et al. Pharmacokinetics and clearance mechanisms of anti-IgE:IgE monoclonal and polyclonal complexes [abstract], *Pharm Res* 1997;14:S217
7. National Institute of Health. Guidelines for the diagnosis and management of asthma. Bethesda (MD); National Institute of Health, National Heart, Lung and Blood Institute; 1997 Jul,. Report No. NIH Publication No. 97-4051.
8. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. *AM Rev Respir Dis*, 1993; 147:832-38.
9. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. *J Clin Epidemiol* 1994; 47:81-7.
10. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsent M. Measuring quality of life in children and asthma. *Quality of Life Research* 1996; 5:35-46.
11. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. *Clin Exp Allergy* 1991; 21:77-83.
12. Roitt IM. Roitt=s essential immunology. In: *Antibodies*, Chapter 3, Ninth Edition. Malden (MA): Blackwell Science Inc., 1997;3:43.
13. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. *Allergy* 2004; 59:701-708

14. Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O, Champain K, Fox H, Thirlwell J, Della Cioppa G. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. *J Eur Respir* 2002; 20: 73-78
15. Holgate ST, Chuchalin AG, Hébert J, Lötvals J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Della Cioppa G. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. *Clin Exp Allergy* 2004; 34: 632-638
16. Holgate S, Bousquet J, Wenzel S, Fox H, Lui J, Castellsague J. Efficacy of omalizumab and anti-immunoglobulin E antibody in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. *Cur Med Research and Opinion* 2001; 17: 233-240
17. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Fowler-Taylor A, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). *Pediatrics* 2001;108:1-10
18. Quentin-Lanier B, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. *Ann Allergy Asthma Immunol* 2003; 91: 154-159
19. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgcock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. *Allergy* 2004; 59: 709-717
20. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Della Cioppa G, van As, A, Gupta, N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. *J Allergy Clin Immunol.* 2001;108(2):184-190.
21. Solèr M, Matz J, Townley, R, Buhl R, O'Brien, J, Fox H, Thirlwell J, Gupta N, Della Chioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. *Eur Respir J.* 2001;18:254-261.
22. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, Staubach P, Jakob T, Stirling RG, Kuna P, Berger W, Maurer M, Rosén K. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. *J Allergy Clin Immunol.* 2013 Jul;132(1):101-9. (GLACIAL)
23. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Giménez-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med.* 2013 Mar 7;368(10):924-35. (ASTERIA II)
24. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Rüeff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V,

Staubach P. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. *J Allergy Clin Immunol.* 2011 Jul;128(1):202-209.e5. (X-QUISITE)

25. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, Spector S, Maurer M. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. *J Allergy Clin Immunol.* 2011 Sep;128(3):567-73.e1. (MYSTIQUE)
26. Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Baskan EB, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O, Spector S, Rosén K. Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1-Antihistamines: A Randomized, Placebo-Controlled Study. *J Invest Dermatol.* 2014 Jul 21. doi: 10.1038/jid.2014.306. (ASTERIA I)
27. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Nast A, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Maurer M. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. *Allergy.* 2014 Jul;69(7):868-87. doi: 10.1111/all.12313. Epub 2014 Apr 30

## PART III: CONSUMER INFORMATION

XOLAIR®  
(omalizumab)

This leaflet is part III of a three-part "Product Monograph" published when XOLAIR® was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about XOLAIR®. Contact your doctor or pharmacist if you have any questions about the drug.

**ABOUT THIS MEDICATION**

Read all of this leaflet carefully before you are given this medicine.

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor, nurse or pharmacist.

What the medication is used for:Asthma

XOLAIR® (omalizumab) is a prescription medicine that has been shown to significantly decrease the incidence of asthma exacerbations and improve control of asthma symptoms in people who:

- Are 12 years of age and above
- Have moderate to severe persistent asthma. This means they have 1 or more of the following:
  - Asthma symptoms every day
  - Daily need for a rescue inhaler
  - 2 or more asthma attacks a week
  - 1 or more nights a week waking up with asthma symptoms
  - below-normal reading (less than 80%) from a tool called a peak flow meter, which measures how well the lungs work
- Have asthma that is triggered by year-round allergens in the air, which is confirmed by a doctor using a simple skin or blood test. This is known as allergic asthma
- Continue to have asthma symptoms even though they are taking inhaled steroids

Chronic Idiopathic Urticaria (CIU)

XOLAIR® (omalizumab) is a prescription medicine to treat Chronic Idiopathic Urticaria (CIU) in adults and adolescents (12 years of age and older) whose symptoms are not well controlled with antihistamines. XOLAIR® provides relief of CIU symptoms such as skin itch and hives.

What it does:What is allergic asthma?

Allergic asthma is how doctors describe a particular type of asthma. In people with this common condition, certain types of allergens can trigger asthma attacks and symptoms, such as coughing, wheezing, and shortness of breath.

You probably know about many of the things that can trigger your asthma. Cat or dog dander, dust mites, and cockroaches

are common examples of year-round allergens. What you may not know is how something as simple as visiting a friend who has a pet can lead to an asthma attack. The reason allergens can trigger asthma attacks is due, in part, to a body chemical called IgE.

What is Chronic Idiopathic Urticaria (CIU)

Chronic Idiopathic Urticaria (CIU) is a skin disease whose symptoms include itching and hives for at least 6 weeks. Persistent symptoms may be daily or episodic. Some people with CIU may also have swelling of the skin.

What is IgE?

IgE is short for immunoglobulin E. This substance, which occurs naturally in your body in small amounts, plays an important role in allergic asthma and CIU.

If you have allergic asthma, your body makes more IgE when you breathe in an allergen that triggers your asthma. This can cause a series of chemical reactions known as the "allergic-inflammatory process in allergic asthma". It can result in 2 things:

- The muscles that surround your airways begin to tighten. This is known as *constriction of the airways*
- Your airways become irritated and swell up. This is known as *inflammation of the airways*

Together, constriction and inflammation of the airways make it harder for you to breathe. This can lead to an asthma attack, also known as exacerbation.

What is XOLAIR®?

XOLAIR® is supplied as a powder in a small glass vial. The powder is dissolved in sterile water for injection before it is injected. Each vial delivers 150 mg of omalizumab.

Asthma

XOLAIR® blocks a substance called immunoglobulin E (also known simply as IgE) which is produced by your body. IgE plays a significant role in causing asthma. Your doctor will measure the amount of IgE with a blood test and determine your body weight before starting the treatment with XOLAIR®. By blocking IgE, XOLAIR® helps stop the allergic-inflammatory process in allergic asthma.

Adding XOLAIR® injections to treatment with inhaled steroids has been clinically proven to help reduce the number of asthma attacks. XOLAIR® has not been proven to work in other allergic conditions.

XOLAIR® is not a rescue medicine and should not be used to treat sudden asthma attacks. It is not a substitute for the medicines you are already taking.

Chronic Idiopathic Urticaria (CIU)

XOLAIR® blocks a substance called immunoglobulin E (also known simply as IgE) which is produced by your body. By binding to IgE, XOLAIR® reduces the activation of certain cells in your body and the release of histamine and other

chemicals. This helps reduce symptoms of CIU, including itching and hives.

**When it should not be used:**

You should not be given XOLAIR®:

If you are hypersensitive (allergic) to omalizumab or any of the other ingredients of XOLAIR® (see below), or if you have ever had an allergic reaction to a XOLAIR® injection.

*Use in children*

Experience with XOLAIR® in children under 12 years of age is insufficient for any recommendations regarding its use to be made.

*Pregnancy*

Ask your doctor, nurse or pharmacist for advice before taking any medicine.

Before starting treatment with XOLAIR®, tell your doctor if you are pregnant or think that you may be pregnant. Your doctor will discuss with you the benefits and potential risks of being given this medicine during pregnancy. Tell your doctor straight away if you become pregnant while being treated with XOLAIR®.

*Breast-feeding*

Ask your doctor, nurse or pharmacist for advice before being given any medicine.

Tell your doctor if you are breast-feeding. It is not known whether omalizumab, the active substance of XOLAIR®, passes into breast milk or in what ways this could affect the baby. Your doctor will discuss with you the benefits and potential risks of being given this medicine while you are breast-feeding.

*Fertility*

There are no human fertility data for XOLAIR®.

*Driving and using machines*

You may experience dizziness, sleepiness or fatigue after receiving XOLAIR®, in which case you should not drive or use machines.

**What the medicinal ingredient is:**

omalizumab

**What the nonmedicinal ingredients are:**

histidine, histidine hydrochloride monohydrate, polysorbate 20 and sucrose

**What dosage forms it comes in:**

Sterile powder for reconstitution, 150 mg vial (125 mg/mL after reconstitution)

in some patients after receiving XOLAIR®. Anaphylaxis is a life-threatening condition. Signs and symptoms of anaphylaxis include difficulty breathing, light-headedness, rash, itching, and swelling of the tongue and throat (see SIDE EFFECTS AND WHAT TO DO ABOUT THEM).

Anaphylaxis from XOLAIR® can happen as early as after the first injection or hours later, and/or after any XOLAIR® injection. Your doctor, or nurse should watch you for some time in the office or clinic for signs and symptoms of anaphylaxis after injecting XOLAIR®. If you have any of the signs or symptoms of anaphylaxis, tell your doctor or nurse immediately, and get emergency medical treatment right away.

Your doctor or nurse should instruct you about starting emergency medical treatment and getting further medical care if you have any signs or symptoms of anaphylaxis after leaving the doctor's office or clinic.

2- Weakness or paralysis of limbs or face, loss of sensation, difficulty speaking or understanding, transient loss of vision in one eye could be symptoms of a transient ischemic attack or stroke. Seek immediate medical attention if you experience any such symptoms.

**BEFORE** you use XOLAIR®, talk to your doctor or pharmacist if you have:

- Hypersensitivity reaction to any drug (Warnings and Precautions)
- Any other known hypersensitivity (Warnings and Precautions)
- Any allergies to this drug or its ingredients or components of the container (Contraindications)

*Parasite infections*

If you are living in a region where parasite infections are frequent or traveling to such a region, please tell your doctor. XOLAIR® may weaken your resistance to such infections. If you are taking a treatment against parasite infection, please tell your doctor. XOLAIR® may reduce the efficacy of your treatment.

**INTERACTIONS WITH THIS MEDICATION**

Please inform your doctor or nurse if you are taking or have recently taken any other medicines, even those not prescribed. Never suddenly stop taking, or change the dose of, your inhaled steroids or any other asthma medicine or of current medicine for CIU you are taking unless your doctor tells you to do so.

XOLAIR® can be used together with other medicines for asthma, as well as with H1 or H2 antihistamines and leukotriene receptor antagonists (LTRAs) for CIU, but it is still important to tell your doctor that you are taking them before you are given XOLAIR®.

**PROPER USE OF THIS MEDICATION**

Your doctor or nurse will give you XOLAIR® as an injection

**WARNINGS AND PRECAUTIONS**

1- A severe allergic reaction called anaphylaxis can happen

just under the skin.

A patient support program has been established to provide you with injection services. Contact your doctor to enroll.

### Asthma

Based on your dose, your doctor will also tell you if you will need 1, 2, or 3 injections per dose. If you need more than 1 injection per dose, each will be given in a different area of your body.

You will receive 150 or 300 mg every four weeks, or 225, 300 or 375 mg every two weeks. You will probably need to continue taking your current asthma medicine during XOLAIR<sup>®</sup> treatment but after 16 weeks you may be able to reduce or stop any other asthma medication that you are taking. Your doctor will discuss this with you. You should not reduce the dose of other asthma medication without first discussing with your doctor, even if you are feeling better.

### Chronic Idiopathic Urticaria (CIU)

XOLAIR<sup>®</sup> 150 mg or 300 mg are administered subcutaneously every 4 weeks. The efficacy of XOLAIR<sup>®</sup> in CIU patients depends on the quantity that is injected.

### Usual dose:

#### Asthma

XOLAIR<sup>®</sup> is given once every 2 or 4 weeks. Your dose will be determined by your body weight and your IgE level, which your doctor will measure with a simple blood test. Based on your dose, your doctor will also tell you if you will need 1, 2, or 3 injections per dose. If you need more than 1 injection, each will be given in a different place on your body.

Because it is a controller or *maintenance medicine*, you will receive XOLAIR<sup>®</sup> on a regular schedule. It is important that you continue to receive your XOLAIR<sup>®</sup> injections even when you are feeling well.

### Chronic Idiopathic Urticaria (CIU)

You will be given 1 or 2 injections at a time every 4 weeks.

Continue taking your current medicine for CIU during XOLAIR<sup>®</sup> treatment. Do not stop taking any medicine without talking to your doctor first.

Continue to use XOLAIR<sup>®</sup> for as long as your doctor tells you to do so.

If you have questions about how long to receive XOLAIR<sup>®</sup>, talk to your doctor or your pharmacist.

### Overdose:

The maximum tolerated dose of XOLAIR<sup>®</sup> has not been determined. Single intravenous doses up to 4000 mg have been administered to patients without evidence of dose-limiting toxicities. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse

reactions or effects and appropriate symptomatic treatment instituted immediately.

If you think you have taken too much XOLAIR<sup>®</sup>, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

## SIDE EFFECTS AND WHAT TO DO ABOUT THEM

As with all medicines, patients treated with XOLAIR<sup>®</sup> can experience side effects.

The side effects caused by XOLAIR<sup>®</sup> are usually mild. In clinical studies, they were about as common in people who were given XOLAIR<sup>®</sup> as those who were given a placebo (or dummy) injection that did not contain omalizumab.

Some patients had a serious allergic reaction called anaphylaxis, occurring at an average of 2 out of 1000 patients (0.2%) or more. Should it happen, anaphylaxis quickly causes symptoms such as rash, itching, and swelling of the tongue and throat, which can make it hard to breathe and can be life threatening. If you think you are having an anaphylactic reaction, get medical attention right away. Please speak with your doctor about this information.

Take special care if you have a disorder where your own immune system attacks part of your own body (autoimmune disease).

A specific type of allergic reaction (serum sickness) has also been observed in patients treated with XOLAIR<sup>®</sup> or similar products. Signs include joint pain, stiffness, rash, fever, swollen/enlarged lymph nodes and occur typically within one to five days after the injection. If you have such a reaction after taking XOLAIR<sup>®</sup>, contact a doctor immediately.

In initial clinical studies in asthma, the number of observed malignancies was uncommon (<1%) in all studied patients who received XOLAIR<sup>®</sup> or a placebo injection containing no medication, with 0.5% reported in patients receiving XOLAIR<sup>®</sup> and 0.2% in patients receiving placebo injections. Results from a review of all the clinical trials now completed (double in size from the initial studies) and also results from a 5 year observational study found that XOLAIR<sup>®</sup> was not associated with an increased risk of malignancy. Please discuss this information with your doctor.

The most common side effects reported in patients who received XOLAIR<sup>®</sup> in clinical studies in asthma and CIU are listed below. This is not a complete list of all side effects reported with XOLAIR<sup>®</sup>.

- Injection-site reaction (bruising, redness, warmth, burning, stinging, or other discomfort around the injection site)
- Viral infections
- Upper respiratory tract infection
- Sinusitis

- Headache
- Sore throat
- Urinary tract infection

These side effects were about as common in patients receiving placebo.

Other less commonly observed side effects included pain, broken bones, leg pain, dizziness, joint pain, muscle pain, joint swelling, and hair loss.

If you notice hives, skin rash, injection site reactions or any side effects not mentioned in this leaflet, please inform your doctor or nurse.

If you experience any of these, tell your doctor straight away.

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

	of some of the following symptoms: Joint pain, stiffness, rash, fever, swollen/enlarged lymph nodes (signs of so-called serum-sickness). When it occurs this is usually between one to five days after injection			
--	--	--	--	--

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

**HOW TO STORE IT**

XOLAIR® is to be stored in a refrigerator (2°-8°C). Do not freeze. Your doctor or nurse will know this.

**REPORTING SUSPECTED SIDE EFFECTS**

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to:
    - Canada Vigilance Program
    - Health Canada
    - Postal Locator 0701E
    - Ottawa, Ontario
    - K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect).

**NOTE:** Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

**MORE INFORMATION**

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Rare Sudden severe allergic reaction (sudden signs of allergy such as rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, fast heartbeat, dizziness and light headedness, shortness of breath, wheezing or trouble breathing)			√
Rare Low blood platelet count with symptoms such as bleeding or bruising more easily than normal			√
Joint appearance of some of the following symptoms: Pain, numbness or tingling in the arms and legs, lumps or raised patches in the skin, weakness and fatigue, loss of appetite and weight loss (signs of so-called “Churg-Strauss syndrome”)			√
Joint appearance			√

This document plus the full product monograph, prepared for health professionals can be found at:  
<http://www.Novartis.ca>  
or by contacting the sponsor, Novartis Pharmaceuticals Canada Inc., at:  
1-800-363-8883  
or by contacting the patient support program at 1-866-996-5247

This leaflet was prepared by  
Novartis Pharmaceuticals Canada Inc.  
Dorval, Quebec  
H9S 1A9

Last revised: February 25, 2015

XOLAIR is a registered trademark